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1.INTRODUCTION 
Mycobacteria that are other than Mycobacterium tuberculosis (MTB) complex and 
Mycobacterium lepraeare known as non-tuberculous mycobacteria (NTM)(1). 
Nontuberculous mycobacteria have traditionally been seen as environmental organisms 
of limited clinical relevance, overshadowed by their more aggressive 
cousin, Mycobacterium tuberculosis. It was not until the HIV pandemic which 
highlighted disseminated Mycobacterium avium complex (MAC) as major opportunistic 
infection syndromes that their significance was recognized by the healthcare community, 
a role which further cemented by the expansion of iatrogenic immunosuppression. 
There are more than 190 species of nontuberculous mycobacteria (NTM)(2). They are 
rod-shaped organisms that have a thick waxy cell wall and they form biofilms that allow 
them to grow in nutrient- and oxygen-poor conditions.The diseases caused can be 
classified into four groups- progressive pulmonary disease, superficial lymphadenitis, 
skin and soft tissue infections and disseminated infections. Disseminated infections are 
typically seen only in immunocompromised individuals. 
On microscopy, they resist decolourisation by acid due to the mycolic acid present in the 
cell wall. Isolation of the organism by culture from a sterile site or multiple positive 
cultures from an unsterile site is necessary for etiological diagnosis. NTM are classified 
based on the rate of growth and pigment production on solid media, preferred one being 
Lowenstein Jensen medium. Slowly growing NTM take 7 days or more to produce 
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mature growth. Rapidly growing NTM grows within 7 days. Slow growers are 
subdivided into three groups based on pigment production- photochromogens (produce 
pigment only in the presence of light), scotochromogens (produces pigment in the 
absence of light) and non-chromogens (does not produce pigment). 
Identification of NTM species is extremely important as the treatment is species-specific. 
Most NTM are intrinsically resistant to or only partially susceptible to the standard anti-
tubercular drugs.  
Biochemical tests like nitrate reduction, aryl sulfatase production, growth in 5%NaCl and 
urease production are traditionally being used for species identification. It is useful only 
for the identification of the most common 10-15 species. It cannot identify most of the 
new species. Moreover, these tests have a prolonged turnaround time, especially for 
slowly growing NTM. Hence, newer methods using molecular detection such asHigh-
Performance Liquid Chromatography (HPLC),Line Probe Assay (LPA), DNA probes, 
Matrix Assisted Laser Desorption Ionization- Time of Flight (MALDI-TOF) and 
sequencingof DNA have been developed which will reduce the turnaround time and can 
detect novel species. 
All Mycobacteria species contain mycolic acids in the cell wall. HPLC uses the principle 
of identification of NTM based on their chromatographic profile of mycolic acids in their 
cell wall. LPA uses reverse hybridization technology targeting the conserved segments of 
DNA like 16S-23S rRNA spacer region and 23s rRNA. PCR amplicons of the target 
region binds to oligonucleotide probes arranged on a membrane strip giving the species 
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identification. Commercial DNA probes are available, targeting the highly conservative 
16S rRNA region of mycobacteria. 
HPLC, LPA and commercial DNA probes have high cost and limited utility as they are 
restricted to identification of the most frequently isolated NTM species. On the other 
hand, MALDI-TOF is a rapid, cost effective and reliable method of identification of 
NTM species.This technology is designed to provide a protein ―fingerprint‖ based on the 
desorbed ions from the cell surfaces.The instrument software automatically acquires and 
analyses the data and generates a profile for comparison to a database of reference spectra 
composed of previously well-characterized isolates giving the species identification of all 
the common and some of the uncommon NTM species. The method is rapid, with 
relatively simple technique and associated with significantly lower consumable costs than 
traditional microbiological identification methods. But the limitation of MALDI-TOF MS 
is that it requires a larger quantity of organism for analysis because there is no 
preamplification step, which can affect the identification of slowly growing NTM. 
Sequencing of 16SrRNA isimportant in a reference laboratory. It is used as a gold 
standard confirmatorymethod for speciation of bacteria including NTM as it identifies the 
newer and unidentified species which are not identified by biochemicalsand other tests. 
However, closely related species like M. abscessus and M. chelonae; M. houstonense and 
M. senegalense; M. intracellulare and M. chimaeracan have sequence similarity of > 97 
% in the 16S rRNA region and hence cannot differentiated. Sequencing of other targets 
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like16S-23S Internal Transcribed Spacer (ITS), rpoB gene, hsp65gene will help to 
overcome the above problem. 
This study is the standardization of the molecular methods of NTM identification i.e., 
DNA sequencing of 16S rRNA and ITS regions and evaluation of MALDI-TOF against 
this sequencing methods. MALDI-TOF is a rapid and accurate method of proteomics-
based identification, which can be a part of the routine diagnostic armamentarium.This 
will enable early and accurate identification of NTM causing disease and therefore help 
in appropriate management of patients. 
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2.AIM & OBJECTIVES 
 
AIM:  
• Evaluation of MALDI TOF and molecular sequencing for accurate identification 
of Non-Tuberculous Mycobacteria 
OBJECTIVES: 
1. Standardize 16S rRNA and ITS sequencing methods and evaluate Matrix Assisted 
Laser Desorption/Ionization- Time of Flight(MALDI- TOF) 
2. Comparison of MALDI-TOF against the above sequencing techniques 
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3.REVIEW OF LITERATURE  
3.0 HISTORY 
Mycobacterium (Greek origin. myces - fungus; bakterion - small rod) is without doubt 
one of the most clinically significant and extensively studied organisms of bacterial taxa. 
Tuberculosis and leprosy, which are the most important diseases caused due to 
mycobacteria, have been recognized throughout history(3,4).  Mycobacterium leprae 
(originally named Bacterium leprae) was discovered by Armauer Hansen from unstained 
material in 1873 and the staining method was developed and observed by Albert Neisser 
in 1880(5). The clinical interest in mycobacteria began with the work of Robert Koch in 
the late 1800s, who detected the tubercle bacillus (originally named Bacterium 
tuberculosis) in 1882 from stained infected tissue and cultivated the organism on 
inspissated serum medium(6).  
All members of the genus Mycobacterium other than the Mycobacterium tuberculosis 
complex and Mycobacterium leprae are collectively labeled as environmental 
mycobacteria or nontuberculous mycobacteria (NTM). Before the end of the 19
th
 century, 
bovine, avian, reptilian, piscine, and saprophytic varieties of mycobacteria had been 
described(7).  
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Table 1. Early case reports of NON-TUBERCULOUSMYCOBACTERIA: 
1885 - Alvarez and Tavel et al describes Mycobacterium smegmatis (8). 
1900 - case report by Marzinowski of a rapidly growing AFB, from the tonsillar crypt 
and sputum of two patients(9).  
1904- case report by Lichtenstein with description of thin, elongated AFB in the 
sputum of a patient who had recurrent attacks of hemoptysis and calls it as ―pseudo 
tubercle bacilli‖(10). 
1904- the first report of a chronic injection site abscess caused by acid fast bacilli (11).  
1918- AFB are noted in the chronic pustular skin lesions of a soldier from England 
who had been wounded in battle (12). 
1926- Aronson identifies the cause of a disease in salt water fish in the Philadelphia 
aquarium as mycobacterial and named it as Mycobacterium marinum. He described the 
colonies as " a lemon-yellow color which later became a deep orange," (13).  
1936-  Steenken and Landau make an important observation that some colonies of non-
tuberculous mycobacteria changed from white to chromogenic "when left at room 
temperature and exposed to light‖(14).  
1938- da Costa Cruz describes acid fast bacilli from the injection site abscess of a 25-
year-old woman and namedit as Mycobacterium fortuitum(15) 
1951 - Linell publishes a paper describing a new mycobacterial disease of man from 
skin lesions and the causative bacillus was named Mycobacterium ulcerans(16). 
1943- Feldman and co-workers reported the recovery of an avian like bacillus from a 
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man with silico-tuberculosis(17). This organism was later shown to be Mycobacterium 
avium by serological tests(18). 
1953 - Frerich and Moore describes another novel species Mycobacterium abscessus 
from a patient with subcutaneous abscess-like lesion of the gluteal region(19).  
Gibson JB discovers that NTM parasitize the damaged lung(20).Buhler and Pollak 
publishes 2 cases of pulmonary infection caused by a  "yellow bacillus" and the 
descriptions of the organism now called Mycobacterium kansasii(21). 
 
Despite sporadic reports of the isolation of many varieties of NTM from clinical 
specimens in the early part of the twentieth century, the only mycobacteria that were 
taken seriously as a cause of human disease were those of Mycobacterium tuberculosis 
and Mycobacterium bovis.  
However, in the early 1950s, after it had become routine to culture rather than to carry 
out only staining of specimens for acid-fast bacilli (AFB), and when the prevalence of 
tuberculosis began to decrease as the social and economic status improved, a new concept 
about NTM infection began to arise. This was a result of keener bacteriologic and clinical 
correlation, as well as a better understanding of the relationship between weak skin test 
reactions to tuberculin and infection with organisms other than the tubercle bacillus(22). 
Finally, in 1954, Timpe and Runyon correlated the known facts about the relationship 
between human pulmonary disease and NTM and provided the first working 
classification of the organisms(23).  
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3.1 EPIDEMIOLOGY 
NTMwere considered as colonizers or ignored as environmental contaminants in the past. 
But the scenario has changed now and they are increasingly being recognized as 
important pathogens in both immunocompromised or immunosuppressed and even 
immunocompetent individuals. The rates of NTM infection have increased significantly 
in recent years, and rates vary widely depending on the demography and geographic 
location. Most epidemiological studies and case reports are from developed nations. 
However, in countries like India, NTM diseases often goes unrecognized and are 
misdiagnosed. The pulmonary disease due toNTM are often misidentified as tuberculosis. 
3.1.1 EPIDEMIOLOGY BEFORE AIDS EPIDEMIC 
Diseases caused by the NTM were sporadic in nature before the AIDS epidemic. Cases 
were chronic in nature resembling Pulmonary tuberculosis (TB),Mycobacterium kansasii 
and Mycobacterium aviumcomplex(MAC) being the most common pathogens. Most 
cases were in middle-aged men in their sixth decade of life who had previous chronic 
lung diseases like pneumoconiosis, past tuberculosis, chronic bronchitis, chronic 
obstructive pulmonary disease, bronchiectasis or chronic aspiration from esophageal 
diseases. Less common presentations were cervical lymphadenitis, skin abscesses, or, in 
very rare cases, disseminated disease(24,25). 
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3.1.2 EPIDEMIOLOGY AFTER AIDS EPIDEMIC 
The AIDS epidemic in the 1980s brought a dramatic change to the epidemiology of NTM 
infection. NTMinfections are primarily confined to respiratory system in 
immunocompetent individuals. But, in individuals with AIDS and other 
immunodeficiencies, it can lead to disseminated infections. Disseminated MAC 
infections were one of the opportunistic infections which increased dramatically 
following the AIDS epidemic. There were only 78 cases of disseminated NTM infections 
reported before the AIDS epidemic(24). But, according to the CDC, during June 1,1981 
through August 31, 1987, there were 2,269 patients with disseminated NTM among the 
41,349 patients with AIDS. Ninety six percent of these infections were due to MAC.  The 
prevalence of MAC infections were reported to be as high as 50% among the AIDS 
patients in various studies during early 1990s(26). 
3.1.3 BURDEN OF NTM DISEASES-GLOBAL 
The exact rate or frequency of infections due to the different species of NTM is not 
known. In many countries including the United States, diseases due to NTM are not 
notifiable. This has led to a gap in our knowledge on the incidence and prevalence of the 
disease. Furthermore, most studies use the indicator called "isolation prevalence" as a 
surrogate marker for the diseaseprevalence, though the mere isolation of an NTM species 
does not necessarily indicate disease. If we look at available data, it is clear that the 
burden of NTM disease has been increasing in developed nations likeUnited States where 
the incidence of TB is low and there is excellent infrastructure to diagnose the 
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disease(27–29).The most common NTM species causing human disease in the United 
States are MAC and Mycobacterium kansasii. In a systematic review which included 22 
studies that evaluated  the trends in the rate of NTM disease across the United States, 
Canada, Europe, Australia, and Japan between 1946 and 2014, the incidence of  NTM 
diseases increased  by  75 percent  in  the above regions (30). 
3.1.4 BURDEN OF NTM DISEASES-INDIA 
In developing countries like India, the burden of NTM diseases are under reported due to 
misdiagnosis, lack of diagnostics and awareness of the disease. The overall rate of 
isolation of NTM has been reported to range from 0.5% to 8.6%. There is no data 
available on their geographical distribution(31). Prevalence of clinically significant NTM 
among specimens received in a study from north India during 2013-14 was 1.2% with 
Mycobacterium intracellulare being the most common species (32). A retrospective 
study from a tertiary care centre in south India during the time period 1999-2004 found 
that the prevalence of NTM was 3.9%.and the most commonly identified species  were 
Mycobacterium chelonae and Mycobacterium fortuitum(33). In a study from central India 
in Madhya Pradesh during the period 2013-2015, 263 (29%) out of 906 mycobacterial 
culture isolates were identified as NTM. Among these, the predominant species were 
Mycobacterium abscessus followed by Mycobacterium fortuitum, Mycobacterium 
intracellulare and Mycobacterium chelonae(34). 
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3.2 ETIOLOGICAL AGENT 
The term non-tuberculous mycobacteria (NTM) refers to those mycobacterial species 
other than the Mycobacterium tuberculosis complex (M. bovis, M. africanum, M. microti, 
M. canetti, M. caprae, M. pinnipedii, M suricattae and M. mungi) and those organisms 
causing leprosy (M. leprae and M. lepromatosis)(35).They are known by various 
synonyms like ―atypical, ‖anonymous,‖ ―mycobacteria other than tuberculosis,‖ 
―environmental,‖ ―environmental opportunistic‖, and most commonly, ―nontuberculous, 
―or ―NTM.‖(24) 
3.2.1 TAXONOMY  
Classification of mycobacteria began in 1896 by Lehmann and Neumann. They proposed 
the genus Mycobacterium to include the tubercle and leprosy bacilli, organisms which 
had previously been classified as Bacterium tuberculosis and Bacterium leprae. The 
number of validly described species, including synonyms, of Mycobacterium currently 
stands at 197(2).  
Table. 2 Taxonomy of Non-Tuberculous Mycobacteria– 
Rank Reference  
Kingdom -Bacteria  (Cavalier-Smith, 2002)(36) 
Subkingdom -Posibacteria (Cavalier-Smith, 2002) 
Phylum- Actinobacteria (Cavalier-Smith, 2002) 
Order Corynebacteriales (Magee and Ward, 2015) (37) 
Suborder- Corynebacterineae (Stackebrandt E, 1997)(38) 
Family- Mycobacteriaceae (Chester, 1897)(39) 
Genus- Mycobacterium (Lehmann and Neumann, 1896)(40) 
20 
 
ORDER Corynebacteriales- Characteristics- 
Order Corynebacteriales form a distinct monophyletic branch in the 16S rRNA 
actinobacterial gene tree. It encompasses the families Corynebacteriaceae; Gordoniaceae; 
Mycobacteriaceae; Nocardiaceae; Segniliparaceae; Tsukamurellaceae; and the genera 
Hoyosella and Turicella(41). They are aerobic or facultatively anaerobic, grampositive 
and catalasepositive actinomycetes which may form a branched substrate mycelium that 
fragments into coccoid-to rod-shaped element or presents as branched filaments, cocci, or 
pleomorphic forms. They are chemoorganotrophic. The cell wall peptidoglycan contains 
meso‐ diaminopimelic acid and is of the A1γ type. Arabinose and galactose are major 
cell wall sugars.The polar lipids of the plasma membrane are composed of hydrophilic 
head and fatty acid chains. Palmitic, octadecenoic and tuberculostearic are the major fatty 
acid constituents(42).Mycolic acids (2-alkyl, 3-hydroxy long-chain fatty acids) are the 
hallmark of the cell envelope. Members of families and genera classified in the order 
Corynebacteriales can be distinguished from one another and from corresponding taxa in 
the phylum Actinobacteria by taxon-specific 16S rRNA oligonucleotide sequences. This 
should be supported by chemical markers like fatty acid pattern, number of carbon atoms 
in mycolic acid, fatty acids released on pyrolysis, major menaquinone and phospholipid 
type. 
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FIGURE 1. Order Corynebacteriales (Adapted from Bergey‘s Manual® of Systematic 
Bacteriology: Volume Five: the Actinobacteria(41)) 
a- Fatty acid classification according to Kroppenstedt. ()-Numbers refer to the type of 
fatty acid biosynthetic pathway and letters to the types of fatty acids (FA) 
synthesized. 
b- Mycolic acid size (number of carbons) and fatty acids released on pyrolysis were 
detected by the use of GC (Gas Chromatography) and MS (Mass Spectrometry)  
c- MK‐ 9(H2), notation for dihydrogenated menaquinone with nine isoprene units 
d- Characteristic phospholipids: PI, nitrogenous phospholipids absent (with 
phosphatidylglycerol variable); PII, only phosphatidylethanolamine 
e- The wall chemotype of Segniliparus has still to be established.(43) 
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FAMILY Mycobacteriaceae 
The family Mycobacteriaceae contains the type genus Mycobacterium. Mycobacteria are 
aerobic to microaerophilic actinomycetes which usually form slightly curved or straight, 
nonmotile rods [(0.2-0.6) X (1.0-10) µm]. Cells are acid-fast at some stages of growth, 
and are considered gram positive although they are not readily stained by Gram's method. 
They do not form capsules, conidia, or endospores, rarely exhibit visible aerial hyphae, 
are catalase positive, produce acid from sugars oxidatively, and, with the exception of 
strains which do not grow in vitro, can be divided into rapid and slow growers. It is also 
characterized by the presence of mycolic acids with 60-90 number of carbon atoms and 
the predominance of dihydrogenated menaquinones with nine isoprene unit, 
MK‐ 9(H2)(37). 
GENUS Mycobacterium 
The genus encompasses saprophytes, as well as facultative and obligate pathogens. Four 
groups of human pathogens are recognized in the Mycobacterium genus: Mycobacterium 
tuberculosis complex, Mycobacterium leprae, slowly growing NTM and rapidly growing 
NTM(43,44). 
Genus characteristics are as follows:  
1) Acid –alcohol fastness (resists decolorization by an acidified alcohol after staining 
with a primary stain. 
2) The presence of mycolic acids which can been cleaved into fatty acid methyl esters by 
pyrolysis. 
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3) 61-71 % G+C content of the DNA, Mycobacterium leprae being the only exception 
(51%). 
3.2.2 CLASSIFICATION OF MYCOBACTERIA 
One of the earliest classifications of NTM was by Krause in 1920. He reviewed the 
existing knowledge of the acid-fast bacilli that were widely distributed in nature during 
that period. He divided them into three groups- the free-living or saprophytic bacilli; 
those associated with healthy animals or their products (bacilli in dung, milk, and butter), 
and those associated with tuberculosis-like disease of cold-blooded animals like turtles, 
fish, and snakes. He documented existence of 40 different varieties of acid-fast bacilli 
exclusive of the tubercle bacillus (13). 
The general view of mycobacteriologists by 1950 was that there were three varieties or 
species of M. tuberculosis: human, bovine and avian. In addition to these, there were 
several species of well-known "saprophytic" organisms like M. phlei and M. fortuitum. 
Several attempts to classify the mycobacteria were made by bacteriologists, but were not 
widely accepted by clinicians. As culturing of sputum became common practice during 
the post-WorldWar II era and more ―atypical‖ mycobacteria were identified, the need for 
a clinically applicable method to classify mycobacteria was needed. By 1954, Timpe and 
Runyon developed a system of classification that suited the needs of the time(23,45). In 
this classification, mycobacteria, apart from those in the M. tuberculosis complex and 
members of non-cultivable taxa, were divided into four overtly artificial groups based on 
growth rates and ability to produce pigment. 
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Table 3. The Timpe-Runyon Classification 
Group Pigment Rate of 
growth 
Examples 
I Photochromogenic 14-21 days M.kansasii, M. marinum, M. simiae, M. 
asiaticum 
II Scotochromogenic 10-14 days M.gordonae, M. scrofulaceum, M. 
flavescens 
III Nonphotochromogenic 14-21 days MAC, M. xenopi, M. ulcerans, M. 
terrae, M. haemophilum 
IV Variable 5-7 days M. abscessus, M. chelonae, M. fortuitum 
Ref: Runyon EH, 1959(45) 
Types I, II, and III, slow growers, take 7 days or more to grow and are differentiated by 
the colour of colonies. Members within the two groups- slow and rapid growers- can be 
distinguished using a combination of phenotypic properties which will be described later. 
The taxonomic status of some of these species was, however, uncertain and it is largely 
due to the efforts of the International Working Group of Mycobacterial Taxonomy 
(IWGMT) that major progress has been made in this area(46). Another clinically oriented 
classification is the Woods and Washington Classification (47). 
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Table 4. Woods and Washington Classification scheme 
1. Species Potentially Pathogenic in Humans 
Slow growers: 
M. avium complex                                            
M. kansasii 
M. scrofulaceum 
M. xenopi 
M. szulgai 
M. haemophilum 
M. celatum 
Rapid growers:  
M. fortuitum group, M. chelonae/abscessus group 
 
 
 
M. malmoense 
M. simiae 
M. genavense 
M. marinum 
M. ulcerans 
 
 
 
 
 
2. Saprophytic Mycobacteria Rarely Causing disease in Humans 
M. gordonae 
M. asiaticum 
M. terrae 
M. triviale 
M. shimoidei 
M. gastri 
M. nonchromogenicum 
M. paratuberculosis 
3. Species with an Intermediate Growth Rate 
M. flavescens 
 
4.Other Rapidly Growing Species  
M. thermoresistible 
M. neoaurum 
M. smegmatis group 
M. mucogenicum group 
M. mageritense 
M. wolinskyi 
 
 
The availability of molecular methods has made the Runyon classification obsolete for 
clinical purposes andresulted in a marked increase in the identification of new species. 
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Sequencing of 16S rRNA and phylogenetic analysis can be used to distinguish various 
species. 
 
FIGURE 3. Phylogenetic tree of NTM, based on the 16S rRNA.(Adapted from Tortoli 
et al, 2014) 
Table 5. Clinically important slowly growing NTM 
Mycobacterium avium 
complex (MAC) 
M.avium subsp. avium, M. avium subsp. paratuberculosis, M. 
avium subsp. silvaticum, M. avium subsp. hominisuis; 
M. intracellulare; M. chimaera, M. yongonense, M. timonense, 
M. marseillense, M. columbiense, M. arosiense, M. vulneris 
M.simiae complex M.simiae, M.lentiflavum, M.sherrisii, M.heidelbergense, 
M.parmense, M.europaeum, M. parascrofulaceum, 
M.lentiflavum, M. triplex, M.florentinum 
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M. terrae complex M.terrae, M.nonchromogenicum, M.heraklionense, 
M.kumamotonense, M.longobardum, M.arupense, 
M.nonchromogenicum 
Others:M.kansasii, M.scrofulaceum, M.marinum, M.malmoense, M.szulgai, M.celatum, 
M.interjectum, M.conspicuum, M.ulcerans, M.haemophilum, M.xenopi, M.malmoense 
 
Table 6. Clinically important rapidly growing NTM 
Six major groups of RGM 
[based on pigmentation and 
genetic relatedness] 
Species within group  
 
Mycobacterium fortuitum 
group   
M. fortuitum, M. peregrinum, M. senegalense, M. 
setense, M. septicum, M. porcinum, M. houstonense, M. 
boenickei, M. brisbanense, M. neworleansense 
Mycobacterium chelonae/ 
abscessus group 
M. chelonae, M. immunogenum, M. abscessus subsp. 
abscessus (formerly M. abscessus), M. abscessus subsp. 
bolletii (formerly M. massiliense and M. bolletii), M. 
salmoniphilum, “M. franklinii” 
M. mucogenicum group  M. mucogenicum, M. aubagnense, M. phocaicum 
M. smegmatis group M. smegmatis (formerly M. smegmatis sensu stricto), M. 
goodii 
Early pigmented RGM M. neoaurum, M. canariasense, M. cosmeticum, M. 
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monacense, M. bacteremicum 
M. mageritense/M. wolinskyi 
group 
M. mageritense, M. wolinskyi 
 
3.3 STRUCTURE OF NON-TUBERCULOUS MYCOBACTERIA 
The chemical nature of mycobacterial envelope is different from those of both Gram-
positive and Gram-negative bacteria; for example, the lipid content of the cell envelope 
of Mycobacteria may represent up to 40% of the cell dry mass, compared to less than 5% 
in other Gram-positive bacteria and only 10% in Gram-negative bacteria(48).They give 
the property of acid fastness and the tendency of cells to clump together. Permeability to 
drugs and other metabolites is 10–100-fold lower than that of the notably impermeable 
bacillus like Pseudomonas aeruginosa.  
Mycobacterial envelope consists of a plasma membrane, which is homologous to plasma 
membranes of other bacteria, surrounded by a complex wall of carbohydrates and lipids 
organized in an outer membrane bilayer, which is in turn surrounded by an outer 
layer,called ‗capsule‘ in the case of pathogenic species(49). A compartment analogous to 
the periplasmic space in Gram-negative bacteria also exists in Mycobacteria. Cryo-
electron microscopy,which maintained the integrity of the lipid structures, was performed 
for the detailed ultrastructural analysis of Mycobacteria (50). 
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FIGURE 4. Cell wall structure of Mycobacteria.[AG, arabinogalactan; PG, 
peptidoglycan ;TDM- Trehalose dimycolate; PL- Phospholipid; TMM- Trehalose 
monomycolates; GL- Glycopeptolipid]-Adapted from Marrakchi et al, 2014 (51). 
Plasma membrane: On visual inspection of ultrathin section, the plasma membrane of the 
Mycobacteria appears similar to other biological plasma membrane. Lipid composition of 
the plasma membranes between those of rapid- and slow-growing Mycobacterium species 
is the same. Polar lipids, mainly phospholipids, assemble into a lipid bilayer in 
association with the protein(52). Palmitic, octadecenoic and 10-methyloctadecanoic (or 
tuberculostearic) acid are the major fatty acid constituents. Main phospholipids (PL) are 
phosphatidylinositol mannosides, phosphatidylglycerol, cardiolipin and 
phosphatidylethanolamine. 
Periplasmic space: It exist between the plasma membrane and cell wall. They are 
approximately 20-nm thick and they contain a granular layer. 
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Cell wall: The wall of mycobacteria is a tripartite complex which consists of a covalently 
linked ‗cell wall skeleton‘, composed mainly of peptidoglycan (PG), arabinogalactan 
(AG) and Mycomembrane enclosed by a noncovalently linked capsule made up of 
polysaccharides and proteins. This is called the ―mycolyl arabinogalactan peptidoglycan‖ 
(mAGP) complex(53). It gives shape to the cell.  
Peptidoglycan: it is composed of repeating units of N-acetylglucosamine and N-
acetyl/glycolylmuramic acid cross-linked by short peptides and has major amounts of 
meso-diaminopimelic acid, arabinose, and galactose. 
Arabinogalactan: it is a complex, branched heteropolysaccharide. It contains a galactan 
chain composed of alternating 5- and 6-linked d-galactofuranosyl residues. 
Mycolic acids of mycobacteria are very long-chain (60-90 carbon atoms) α-branched and 
β-hydroxylated fatty acids with an aliphatic side chain at position 2(49). On pyrolysis, 
mycolic acid methyl esters yield long-chain fatty acid methyl esters. The mycolic acid 
methyl esters of mycobacteria yield C22 to C26 fatty acid methyl esters on pyrolysis by 
gas chromatography. Non-mycobacterial mycolic acids have relatively simple structures 
and vary in chain length (22-74 carbon atoms) and in the number of cis double bonds (0-
5) and release shorter fatty methyl acid esters.  
The mycomembrane exhibits a non-conventional bilayer organization in which the inner 
leaflet is made of very long-chain Mycolic acid (MA) linked to Arabinogalactan (AG), 
which in turn is covalently attached to Peptidoglycan (PG). The outer leaflet of the 
mycomembrane is presumably composed of free - i.e. non-covalently bound to the cell – 
lipids – which include phospholipids (PL), trehalose monomycolates (TMM) and 
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trehalose dimycolates(TDM), glycopeptidolipids (GPL), and lipoglycans. The 
glycopeptidolipids (GPL) are produced by NTM but not Mycobacterium tuberculosis. 
The composition and concentration of GPL vary between NTM species and can impact 
colony morphology. M. abscessus-containing GPL show a smooth morphotype; those 
lackingGPL manifest as rough morphotypes. M. abscessus smooth variants survive in the 
environment, whereas the rough variant appears to arise only during the course of 
infection(54).To deter recognition by toll-like receptor 2 (TLR2) present on innate 
immune cells, GPL of smooth M. abscessus form an outer layer that covers the 
mycobacterial TLR2 ligand phosphatidyl-myo-inositol mannosides, effectively 
preventing the glycolipid from being recognized by TLR2 (55,56). 
Outer layer (OL): it is also called as the capsule, in case of pathogenic species. The 
capsule of mycobacterial pathogens such as Mycobacterium tuberculosis is mainly 
composed of glucan and proteins, with only a tiny amount of lipids whereas the outer 
layer of non-pathogens is primarily constituted of proteins. 
They can be stained with basic dyes such as carbol fuchsin and cannot be decolorized 
with acid-alcohol. This unique property is termed ―acid-fastness‖ and is the basis of the 
Ziehl-Neelsen staining technique for the identification of mycobacteria. The acid-alcohol- 
fast property of these bacteria could be related to the lipid barrier of the wall mycolyl-
arabinogalactan hindering the penetration of the acid. This indicates that differences in 
the degree of acid-alcohol fastness between different organisms might reflect variations 
in the chemical nature of their walls(57).  
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3.4 HABITAT OF NON-TUBERCULOUS MYCOBACTERIA 
NTMs are ubiquitous in the natural and man-made environment. They are natural 
inhabitants of soils, rivers, lakes and streams(58). They enter the surface waters from the 
soil, especially acidic pine forest or coastal swamp soils. They have predilection for soil 
with an acidic pH and the presence of humic and fulvic acids, which stimulate their 
growth. Due to the presence of lipid-rich outer membrane, they are resistant to chlorine, 
chloramine and ozone. In fact, NTMs are 40-fold more resistant to chlorine than 
Pseudomonas aeruginosa and 500-fold more resistant to chlorine than Escherichia 
coli(59). Coupled with the ability to survive in low nutrient settings, it can multiply and 
reach end users of the water supply. NTM can also survive in the drinking water pipeline 
system through biofilm formation leading to its slow and persistent release. They can 
easily be aerosolized due to the hydrophobic nature and get released in showers, water 
taps, hot tubs or spas, and humidifiers of air conditioning system(60). 
3.4.1 TRANSMISSION OF NON-TUBERCULOUS MYCOBACTERIA 
Unlike Mycobacterium tuberculosis, there are no convincing data demonstrating human-
to-human transmission of infection. Thus, the concept prevails that these organisms are 
acquired from the environmentvia inhalation (most common), ingestion, and skin-to-skin 
contact(61). Water is the primary source of MAC infection in humans(62). DNA-based 
fingerprints of Mycobacterium avium isolates from AIDS patients in a study were 
identical to those of isolates recovered from their drinking water(63). There are several 
theories regarding the increasing incidence of infection. One relates to showering rather 
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than bathing in a tub. Showering in a closed stall exposes the user to a higher aerosol 
concentration of NTM(64). In addition, to save energy, water heaters have lower 
temperatures now, which could allow more NTM growth in the water. Water filters may 
serve as a breeding ground for organisms and allow for higher concentrations of 
mycobacteria compared to unfiltered water(65). Furthermore, environmental exposure to 
these organisms must be common because data from several countries shows that a 
substantial fraction of children have delayed cutaneous hypersensitivity responses to 
MAC antigens, a fraction that increases with age. Finally, there are data to indicate that 
aspiration of water, through swallowing or gastroesophageal reflux, is a way that 
mycobacteria gain access to the lungs to cause disease(66).  
Skin and soft tissue infections usually occur due to contact with water and  direct 
inoculation with contaminated intravenous infusion fluids and medicines or unsterile 
injection needles or during trauma (67,68). 
3.4.2 RISK FACTORS ASSOCIATED WITH NTM DISEASE 
Although it is not clear why NTM diseases have been increasing, there are several 
contributing factors, such as, an increase of mycobacterial infection sources in the 
environment, an increase in the number of susceptible individuals, improvements of 
laboratory detection techniques, and increased awareness of NTM diseases(69). Although 
they are found easily in water and soil, infections are not common in the human 
population. Most NTM are significantly less pathogenic than Mycobacterium 
tuberculosis and require some degree of host impairment to result in disease. The host 
34 
 
impairment can either be chronic lung disease or defects in the immune system of which 
the former is more common. NTM disease has been described in association with prior 
tuberculosis, bronchiectasis, cavitary lung disease, chronic obstructive pulmonary disease 
including 1-antitrypsin deficiency, cystic fibrosis, pneumoconiosis, pulmonary alveolar 
proteinosis and chronic lung injury due to aspiration from gastro-esophageal 
disorders(29,70,71). A genetic link has been hypothesized as many females who develop 
bronchiectasis and NTM infection share a similar body type characterized by tall slender 
stature with a higher frequency of pectus excavatum, kyphoscoliosis and mitral valve 
prolapse than females who do not have NTM infection. This condition was first described 
in 1989 and later referred to as the ‗‗Lady Windermere Syndrome‘. referring to the 
chronic suppression of normal cough reflex as portrayed by the character(72,73). A 
number of inherited and acquired defects in the host immune response, particularly those 
that affect the Th1 cell and macrophage pathway, have been associated with increased 
susceptibility to NTM infections. Many of these host immune defects are associated 
especially with disseminated infection.  
Table 7. Host immune defects associated with disseminated NTM infection 
1. Mutations in interferon (IFN)- γ receptor 1, IFN-γ receptor 2, interleukin (IL)-12 
p40 and the IL-12 receptor 
2. Mendelian susceptibility to mycobacterial diseases (MSMD), is caused by genetic 
defects in the mononuclear phagocyte/T helper cell type 1 (Th1) pathway 
3. Auto-antibodies to interferon gamma  
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4. CD4 lymphopenia due to HIV or other causes  
5. Use of TNF-alpha inhibitors, particularly infliximab and adalimumab  
6. Signal transducer and activator of transcription 1 (STAT1) deficiency 
Protective factors-Epidemiologic studies from Europe have suggested that childhood 
immunization with Bacillus Calmette-Guerin (BCG) vaccine is associated with a reduced 
risk of childhood cervical lymphadenitis due to NTM(74). 
3.5 CLINICAL PRESENTATION 
In broad terms, NTM cause four distinct clinical syndromes: 
●Progressive pulmonary disease in older persons caused primarily by Mycobacterium 
avium complex (MAC) and Mycobacterium kansasii 
●Superficial lymphadenitis, especially cervical lymphadenitis, caused mostly by MAC 
andMycobacterium scrofulaceum. 
●Skin and soft tissue infection usually as a consequence of direct inoculation. 
●Disseminated disease in severely immunocompromised patients. 
Table 8.Diseases caused by NTM and the etiologic species: 
Clinical disease Etiologic species 
 Common Unusual 
Chronic 
bronchopulmonary 
disease 
MAC 
M.kansasii 
M.abscessus 
M.malmoense 
M.xenopi 
M.simiae 
M.szulgai 
M.fortuitum 
M.celatum 
M.gordonae 
M.asiaticum 
M.shimodii 
M.smegmatis 
M.haemophilum 
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Lymphadenitis MAC 
M.scrofulaceum 
M.malmoense 
M.fortuitum 
M.chelonae 
M.kansasii 
M.abscessus 
M.haemophilum 
M.lentiflavum 
M.interjectum 
M.heidelbergense 
M.bohemicum 
Skin and soft tissue 
disease 
M.ulcerans 
M.marinum 
M.chelonae 
M.abscessus 
M.fortuitum 
M.kansasii 
M.haemophilum 
M.malmoense 
M.smegmatis 
 
Otitis media M.abscessus 
M.chelonae 
 
Tenosynovitis 
 
MAC 
M.marinum 
M.fortuitum 
M.abscessus 
M.chelonae 
M.kansasii 
M.haemophilum 
M.scofulaceum 
Osteomyelitis M.fortuitum 
M.abscessus 
 
 
M.xenopi 
M.marinum 
M.smegmatis 
M.nonchromogenicum 
M.malmoense 
M.xenopi 
M.szulgai 
M.kansasii 
Catheter related 
infections 
M.fortuitum 
M.abscessus 
M.chelonae 
M.mucogenicum 
M.neoaurum 
M.aurum 
Prosthetic valve 
infections 
M.fortuitum 
M.chelonae 
M.gordonae 
Surgical site infections M.fortuitum M.simiae 
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M.abscessus 
M.chelonae 
Reference: Wagner et al,2004(75) 
3.5.1 PULMONARY DISEASE 
NTM can cause three distinct types of pulmonary disease: fibrocavitary disease, nodular-
bronchiectatic disease and hypersensitivity pneumonitis. When NTM lung disease 
initially gained interest in the late 1950s, it was mainly a disease of men who were miners 
and smokers; their upper lobe cavitary disease was difficult to distinguish from 
pulmonary tuberculosis. They were older than the usual population at the sanatoria with 
limited response to treatment. During the 1980s, the nodular bronchiectatic form was first 
noticed in mainly female patients without a history of chronic lung disease, defined by 
nodular and bronchiectatic lesions radiologically and predominantly affecting the middle 
lobe and lingula. More than a decade later, hypersensitivity pneumonitis was reported, 
often related to exposure to aerosols generated by indoor hot tubs or metalworking fluid. 
Most common agents associated with pulmonary disease are Mycobacterium avium, 
Mycobacterium intracellulare, Mycobacterium. kansasii, Mycobacterium malmoense 
(Europe), Mycobacterium xenopi (outbreaks linked to hot water systems in buildings), 
and Mycobacterium simiae (linked to groundwater sources). 
 In the more familiar fibrocavitary form, upper lobe disease occurs most commonly in 
older male smokers with chronic pulmonary symptoms due to underlying lung disease. 
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Symptoms and radiographic changes may be difficult to differentiate from the underlying 
disease. It usually progresses faster than the nodular type. These patients are almost 
universally diagnosed as a consequence of suspected tuberculosis. 
The nodular-bronchiectatic form of MAC lung disease appears most frequently in 
nonsmoking women over the age of 50 who do not have a history of underlying lung 
disease, but invariably have bronchiectasis at the time of NTM lung disease diagnosis. 
Body morphotype is a possible predisposition to this second form of disease. Some 
patients with fibronodular NTM lung disease appear to have similar clinical 
characteristics and body types, including scoliosis, pectus excavatum, mitral valve 
prolapse, and joint hypermobility(76,77).  
Hypersensitivity pneumonitis is an occupational disease very frequent among people 
using metal-working ﬂuids.Cases have also been described in immunocompetent 
individuals with history of exposure to hot water aerosols from hot tubs/spa pools (known 
as ―hot tub lung‖), showers, and swimming pools. It has a subacute presentation with 
dyspnea and fever. Rapid growers,in particular Mycobacterium immunogenum, are most 
frequently involved(78).  
Patients afﬂicted with cystic ﬁbrosis, a genetic disease, are highly susceptible to bacterial 
infections of the chest. Infections as a result of NTM have increasingly been reported 
with several species, MAC being the most common, followed by Mycobacterium 
abscessusin patients withCFTR gene (79). 
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In lipoid pneumonia, which is a speciﬁc form of lung inﬂammation that develops when 
lipids enter the bronchial tree, a strong association with the isolation of mycobacteria, 
predominantly comprising rapid growers, has been reported, although a causal correlation 
has not been demonstrated(80). 
3.5.2 LYMPHADENITIS 
Lymphadenitis caused by NTM usually affects lymph nodes at a single site. The 
submandibular and cervical lymph nodes are most frequently affected, although axillary 
and inguinal lymphadenitis have been observed. Patients are typically, though not 
exclusively, children, under the age of 8 years. This disease is relatively benign and most 
patients present with an enlarged lymph node without constitutional symptoms; in more 
advanced disease, fluctuating masses with violaceous overlying skin are seen. Even if 
multiple nodes are involved, disease is usually unilateral(81). Until mid-1980s, the 
majority of cases were caused by Mycobacterium scrofulaceum, but now Mycobacterium 
avium is the most common pathogen throughout the developed world(25). 
3.5.3 SKIN AND SOFT TISSUE INFECTIONS 
Localized skin and soft tissue infections due to NTM can be divided into three main 
disease phenotypes; two of them are named diseases.  
Localized NTM skin disease such as the wound or injection site infections are the first 
type. These usually follow medical procedures (contaminated fluids, anesthetic, 
prosthesis like mesh), tattooing or cosmetic therapies that involve incisions in or 
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injections into skin or subcutaneous fat and inoculation of contaminated products. 
Outbreaks have also been noted in beauty salons where foot baths were heavily 
contaminated with NTM. Rapid growers likeMycobacterium fortuitum, Mycobacterium 
chelonae andMycobacterium abscessusare the most frequent causative agents of these 
diseases, but cases caused by recently described new species, such as Mycobacterium 
goodii and Mycobacterium massilienseare increasingly been reported(80,81). 
The second is Buruli ulcer, a severe skin disease caused by Mycobacterium ulcerans that 
progresses from nodular skin lesions into large ulcers. This disease is endemic to parts of 
West Africa and Australia (its former name was Bairnsdale ulcer), but is also seen in 
specific foci in Latin America and China. 
The third is fish tank granuloma (previously also called swimming pool granuloma) 
caused by infection of existing skin abrasions by Mycobacterium marinum, acquired 
during fish- or water-related activities. This usually leads to a single 1-3 cm diameter, 
papulo-nodular, verrucous, or ulcerated granulomatous lesion, mostly on the hand or 
lower arm. The skin disease caused by Mycobacterium marinum may progress to form 
multiple lesions in a typical sporotrichoid pattern. In immunocompromised patients, the 
infection can spread to underlying bony structures, joints and regional lymph nodes.  
3.5.4 DISSEMINATED INFECTIONS 
Disseminated mycobacterial infections develop almost always in severely 
immunocompromised people; the best known are those that affect HIV-infected patients. 
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The respiratory apparatus and the gastrointestinal tract are the two major routes of 
infection. The main symptoms and signs include high fever, diarrhoea, weight loss, 
abdominal pain, sweating, hiccups, anemia, hepatomegaly and splenomegaly. The 
progression of disease may be very rapid and even fatal.  
Disseminated MAC was one of the first opportunistic infections detected in AIDS 
patients; it has been estimated to affect approximately 20-40% of subjects with CD4 
lymphocyte counts less than 50/µL in the absence of effective anti-retroviral therapy(82). 
In such patients, infections caused by M. avium are four-fold more frequent than those 
due to M. intracellulare. Various NTM species are responsible for disseminated 
infections in AIDS patients; among them, M. genavense, a species which remains 
frequently undiagnosed because of its inability to grow on conventional solid media, has 
been estimated to be involved in as high as 10% of the cases attributable to MAC(83). 
Currently, disseminated NTM disease is quite rare in HIV-infected patients due to the 
treatment withHighly Active Antiretroviral Therapy (HAART). An important 
predisposing condition to disseminated mycobacterial infections is the 
immunosuppression established to prevent the rejection of transplanted organs. 
Disseminated mycobacterial infectionsmay develop concomitantly with anticancer 
therapy. They originate, in most cases, from infected catheters and should be suspected 
when a patient remains febrile despite negative blood cultures. 
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Mycobacterium chimaera is an emerging MAC species that has been generally been 
thought to have relatively low virulence, at least as a pulmonary pathogen. Two 
outbreaks of prosthetic valve infections and associated disseminated infection after 
cardiac surgery were associated with Mycobacterium chimaera, in which the source was 
determined through epidemiologic and molecular analysis to be the heater-cooler unit 
used for cardiac bypass procedures, were first described in 2015 in Europe and the United 
States and subsequent clusters have been reported elsewhere(84). 
Catheter-related sepsis, mainly as a result of rapidly growing mycobacteria, has also been 
reported in hemodialysis patients and in surgical patients, primarily following cardiac 
operations. 
In recent years, the administration of antibodies against interferon (IFN)-γ has become a 
frequent practice for the treatment of many immune mediated inflammatory diseases. A 
side effect of the impairment of macrophage activation, consequent to the biological 
therapy, can predispose to mycobacterial infections. A number of cases, mostly 
disseminated, have been reported, some of which do not respond to treatment(80).  
3.6 LABORATORY DIAGNOSIS 
Since NTM are ubiquitous in environment, itsisolation from non-sterile body sites 
especially the respiratory tract does not imply true infection or disease, per se. Repetitive 
isolation, signs of clinical disease, radiological abnormalities, the exact species isolated 
and predisposing conditions of the patient involved are all helpful in determining whether 
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the isolated mycobacteria are to be considered as the causative agent of the patient‘s 
disease. The American Thoracic Society has published a set of diagnostic criteria to aid 
in the diagnosis of NTM.  A combination of clinical, radiologic, and bacteriologic 
features has been suggested for diagnosis of true pulmonary NTM disease. Evaluation 
should include, beside appropriate history and physical examination, chest imaging using 
high- resolution computed tomography (HRCT), unless there is obvious cavitation by 
chest X ray. HRCT views may show scattered areas of bronchiectasis and often mixed 
nodular and cavitary infiltrates, with an occasional ―tree in bud‖ pattern. At least three 
sputum samples need to be collected for AFB smear and culture. These criteria are 
established the best for disease caused by MAC, M. kansasii, and M. abscessus. If 
possible, NTM should be identified at the species level.  
Table 9.Clinical and microbiological criteria for diagnosing nontuberculous 
mycobacterial lung disease  
Clinical (both required) 
1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or a 
high-resolution computed tomography scan(HRCT) that shows multifocal 
bronchiectasis with multiple small nodules AND 
2. Appropriate exclusion of other diagnoses. 
 
Microbiological 
1.  Positive culture results from at least two separate expectorated sputum 
samples; if the results from one are nondiagnostic, repeating sputum smears 
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and cultures should be considered. OR 
2. Positive culture result from at least one bronchial wash or lavage. OR 
3. Transbronchial or other lung biopsy with mycobacterial histopathological 
features (granulomatous inflammation or acid-fast bacilli) and positive 
culture for NTM or biopsy showing mycobacterial histopathological features 
(granulomatous inflammation or acid-fast bacilli) and one or more sputum or 
bronchial washings that are culture positive for NTM. 
Additional considerations 
4. Expert consultation should be obtained when NTM are recovered that are 
either infrequently encountered or that usually represent environmental 
contamination. 
5. Patients who are suspected of having NTM lung disease but do not meet the 
diagnostic criteria should be followed up until the diagnosis is firmly 
established or excluded. 
6. Making the diagnosis of NTM lung disease does not, per se, necessitate the 
institution of therapy, which is a decision based on the potential risks and 
benefits of therapy for individual patients. 
 
Ref: Griffith et al., An Official ATS/IDSA Statement: diagnosis, treatment, and 
prevention of nontuberculous mycobacterial diseases,2007(44) 
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3.6.1 IMAGING 
The radiographic pattern of disease can usually be separated into predominantly cavitary 
versus nodular/bronchiectatic. Some generalizations can be made: Cavitary disease in the 
upper lung zones, similar to pulmonary tuberculosis, is seen in approximately 90 percent 
of patients with M. kansasii infection and perhaps 50 percent of those with 
MACinfection. The cavities caused by these organisms tend to have thinner walls and 
less parenchymal opacity surrounding it than those caused by M. tuberculosis(85,86).  
At least 50 percent of patients with MAC lung disease have radiographic abnormalities 
characterized by nodules associated with bronchiectasis or nodular or bronchiectatic 
disease. The nodules and bronchiectasis are usually present within the same lobe and 
occur most frequently in the right middle lobe and lingula(87).  
Solitary nodules and dense consolidation have also been described. Pleural effusions are 
uncommon, but reactive pleural thickening is frequently seen. 
3.6.2 SMEAR MICROSCOPY  
Acid-fast microscopy is the fastest, easiest, and least-expensive tool for the rapid 
identification of patients with mycobacterial infections, and semiquantitative results 
of smear examinations may be an important aid in determining the clinical significance 
of specimens with NTM isolates. Bacterial cells are generally pleomorphic, ranging from 
long, filamentous forms to short, thick rods. Branching typically is absent or rudimentary. 
However, microscopy is unable to distinguish withinthe Mycobacterium genus and 
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between viable and nonviable mycobacteria. Thesensitivity of microscopy is influenced 
by numerous factors, such as type of specimen, quality of specimen collection, number of 
mycobacteria present in the specimen, method of processing (direct or concentrated), 
method of centrifugation, staining technique and quality of examination. 
Ziehl-Neelsen (ZN) staining has a low sensitivity of 22–43% for a single smear. 
Maximum sensitivity is up to 60% when compared with that of cultures. The threshold of 
detection of AFB in sputum is 10
4
 to 10
5
 bacilli per ml. To overcome the above-
mentioned disadvantages of conventional method of staining, Light-Emitting Diode 
(LED) fluorescence microscope was introduced. It uses an auramine-rhodamine or 
auramine O dye (acid-fast fluorochrome), weaker acid as a decolorizer, and a counter 
stain with a quencher such as potassium permanganate. Fluorescent microscopy has 80-
90% sensitivity compared to culture(88). LEDfluorescent microscopy has been 
recommended by World Health Organisation(WHO) in 2010 as the preferred microscopic 
technique in high burden labs (44,89). 
3.6.3 CULTURE 
Sputum, induced sputum, bronchial washings, bronchoalveolar lavage or transbronchial 
biopsy samples can be used to evaluate individuals suspected to have NTM-pulmonary 
disease. Whenever possible, less invasive sampling should be attempted first to minimize 
procedural risks. Respiratory samples should be processed within 24 hours of collection 
(or refrigerated at 4°C if delays are anticipated) (44).Other samples to be collected are 
lymph node biopsy, blood, exudate, tissue biopsy etc. depending on clinical scenario. 
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Both liquid and solid media are used for mycobacterial culture. Cultures grown on solid 
media allow for the observation of colony morphology, growth rates, species 
categorization based on pigmentation, and quantitation of the infecting organism. Liquid 
systems are more sensitive and reduce the delay in the detection of NTM, but they are 
prone to contamination by other microorganisms and bacterial overgrowth(44). 
Positive sputum cultures for NTM must be interpreted cautiously since these organisms 
have variable virulence and can be recovered from the respiratory tract without causing 
progressive infection (transient infection or colonization). In addition, NTM are common 
in the natural environment and may contaminate laboratory specimens. Tap water 
especially (liquid or frozen) may contain NTM and contaminate clinical and laboratory 
specimens. 
NTM frequently occurs in the context of underlying lung disease as in concurrent 
tuberculosis, which can also cause symptoms. As a result, the distinction between 
transient infection or contamination and true infection is sometimes difficult. Isolation of 
M. gordonae, M. mucogenicum, M. nonchromogenicum, M. haemophilum, M. flavescens, 
M. gastri, M. terrae, or M. triviale indicates probable colonization or contamination. 
These organisms are generally not pathogenic for humans except in the context of severe 
cellular immunodeficiency, such as AIDS. Expert consultation should be obtained when 
NTM are recovered that are either infrequently encountered or that usually represent 
environmental contamination(44). Fortunately, lung disease caused by NTM is often 
indolent, so careful assessment over time is possible. 
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Lowenstein-Jensen (LJ) is a conventional medium which is excellent for the growth of 
both Mycobacterium tuberculosis and NTM(44). Guidelines and Recommendation for 
culture of NTM as per ATS (American Thoracic Society) include two types of medium, 
one solid medium (LJ or Middlebrook medium) and one liquid medium culture system 
BACTEC (Becton-Dickenson Diagnostics), MB Redox (Heipha Diagnostika), 
BacT/ALERT
®
 MP (bioMerieux, France), MGIT (BD Diagnostics) or Septi-check (BD 
Diagnostics).Liquid media require additives such as OADC in order to provide 
enrichment (mixture of bovine albumin, dextrose, catalase, and oleic acid) and PANTA 
antibiotic (mixture of polymyxin B, amphotericin B, nalidixic acid, trimethoprim, and 
azlocillin) to inhibit the growth of contaminants.The conventional method for the growth 
of mycobacteria is time-consuming (6–8 weeks), but they are considered ―gold standard.‖ 
Liquid-based culture has high sensitivity because the growth of mycobacteria can be 
detected within 1–2 weeks. So, they are always used in combination with the 
conventional LJ method. The final report can be sent after 6 weeks if no growth is 
detected in the liquid-based culture and 8 weeks of incubation in case of the LJ 
slants(88). 
Slowly growing mycobacteria need at least 7 days for the growth to appear on solid 
media. Chromogenic NTM species produce pigment that can range from light yellow and 
yellow to orange or even rose-colored. Within the pigmented mycobacteria, the 
photochromogens are nonpigmented in the dark and produce pigmentation only after 
exposure to light. The scotochromogens produce pigment when grown in the dark. The 
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color may intensify with the increasing age of the culture. The nonchromogenic species 
do notproduce pigmentation when grown either in the dark or after exposure to light(57). 
Mycobacteria are categorized as rapid growers, by definition, if they grow on a solid 
medium within 7 days after subculture. The young colonies appear smooth and 
hemispherical, usually with a butyrous or waxy consistency. Colonies of M. fortuitum 
group and M. chelonae/M. abscessus group are typically nonpigmented but may appear 
off-white or faintly cream-colored. Some strains produce rough colonies with short aerial 
hyphae, best observed under a stereomicroscope. The above mycobacteria often have the 
capability of growing on MacConkey agar without crystal violet. Additionally, they may 
grow on routine 5% sheep blood agar, initially appearing as tiny pinpoint colonies. Some 
strains of M. fortuitum may grow within 48 hours. Microbiologists must perform acid-fast 
staining in addition to Gram‘s stain if the correct identification is to be made. The 
bacterial cells appear as short, slender, irregularly staining gram-positive bacilli(90). 
Mycobacterium species differ in the ability to grow at certain temperatures. For slowly 
growing species, the minimum set of temperatures for incubation comprise 30 ± 1°C and 
36 ± 1°C. Most slowly growing mycobacterial species grow well at 35 to 37°C, but 
others, including M. marinum, grow better at a lower temperature (30°C), especially on 
primary isolation. Therefore, samples from skin or lymph nodes and other tissue 
specimens from the body periphery should routinely be incubated both at 30 ± 1°C and at 
36 ± 1°C. Additional media incubated at 22 to 25°C and 42°C may be necessary for 
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optimal growth of some species, such as M. haemophilum (28 to 32°C), M. xenopi (42°C) 
and M. conspicuum (22 to 31°C)(57).  
3.6.4 IMMUNOCHROMATOGRAPHIC TEST 
MPT 64 TB Ag Kit is a simple and rapid immunochromatographic assay developed by 
SD Bioline, which facilitates detection and differentiation of M. tuberculosis complex 
isolates from NTM.Studies reported a sensitivity of up to 97-100% and specificity of up 
to 100%. However, it cannot be used for speciation of NTM(91,92).  
3.6.5 SPECIES IDENTIFICATION 
Because treatments and outcomes differ depending on the NTM species, the accurate 
identiﬁcation of NTM species is very important(93,94) . Traditional biochemical tests 
and high-performance liquid chromatography for NTM identiﬁcation have been replaced 
by molecular methods such as line probe assay, PCR-RFLP (restriction fragment length 
polymorphism), real-time PCR, DNA sequencing, and matrix-assisted laser desorption 
ionization–time of ﬂight (MALDI-TOF)mass spectrometry. 
 
 
3.6.6 BIOCHEMICAL IDENTIFICATION 
The rate of growth, pigmentation of colonies, and various biochemical reactions are used 
for phenotypic identification of NTM species.  
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Table 10. Key biochemical tests for NTM species identification 
1. Nitrate reductase activity 
2. Niacin accumulation test 
3. Tween 80 hydrolysis 
4. Growth on MacConkey agar 
5. Tellurite reduction test 
6. Urease activity 
7. Catalase activity at 68°C 
8. Arylsulfatase production 
9. Tolerance to 5% NaCl 
10. Pyrazinamidase activity 
11. ß-glucosidase activity 
Reference- Koneman‘s Colour Atlas, 7thedition(90).  
The utility of the tests is decreasing currently, especially for the slow growers, as most of 
the novel species cannot be identified using the biochemical tests. 
3.6.7 MOLECULAR METHODS: 
Molecular methods are needed for identification of newer species of NTM that are 
implicated in human infection. However, phenotypic characteristics of NTM such as 
colony morphology, pigmentation, and growth rate must be correlated with molecular 
identiﬁcation. Molecular testing is based on the principle of nucleic acid amplification 
which allows faster and precise identification of the mycobacterium species.  
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3.6.8 LINE PROBE ASSAY 
Line probe assays are based on nucleic acid amplification and reverse hybridization to 
detect various species of NTM from clinical samples and culture isolates. The 
commercial assays available are GenoType
®
Mycobacterium common 
mycobacteria/additional species (CM/AS) assay (Hain Lifescience) and INNOLiPA 
Mycobacteria assay (Innogenetics). This method targets the 23S ribosomal RNA gene 
region, followed by reverse hybridization on nitrocellulose membrane 
strips.GenoType
®
Mycobacterium CM recognizes 15 common Mycobacterium species, 
including M. tuberculosis complex whereas the GenoType
®
MycobacteriumAS is able to 
identify 16 additional less common NTM species.  In this technology, the target 
sequences are first amplified by PCR using biotinylated primers.INNO-LiPA 
MYCOBACTERIA V2 (Innogenetics, Gent, Belgium) is able to determine the presence 
of mycobacteria at the genus level for 16 different species using a broad-range PCR 
directed against the 16S to 23S internal transcribed spacer region. The multiple probes 
are immobilized on a nitrocellulose strip, and the amplified product is applied to the strip, 
which is the reverse of a Southern blot. Lines form at the site of amplicon-probe 
hybridization. Evaluation of GenoType
®
Mycobacterium CM/AS assay showed that 
sensitivity and specificity were 97.9% and 92.4% for the CM kit and 99.3% and 99.4% 
for the AS kit(95). INNO-LiPA was evaluated and found to be 100% sensitive and 94% 
specific(96). 
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Disadvantages: Laborious and needs both a good molecular biology set up and trained 
laboratory personnel.Members of the M. abscessus complex cannot be differentiated 
using this assay. LPA has been found to perform better on culture isolates. 
3.6.9 MALDI-TOF 
Matrix-assisted laser desorption ionization–time of flight(MALDI-TOF) 
massspectrometry is revolutionizing the identification of microorganisms and has been 
recently applied to the identification of mycobacteria. MALDI-TOF mass spectrometry 
analysis of mycobacteria involves several steps including inactivation, extraction, and 
analysis. Several different methods have been described for the inactivation and 
extraction of mycobacterial cells. Inactivation can be done by ethanol or heat or 
mechanical lysis using either a micropestle or by bead beating techniques. Extraction is 
performed by adding formic acid and acetonitrile to the inactivated mycobacterial cells. 
All inactivation and extraction steps should be performed within a BSL- 3 facility using 
the appropriate personal protective equipment (PPE). Following inactivation and 
extraction, an aliquot is spotted onto a solid target support plate and overlaid with a 
chemical matrix (for example, alpha-cyano-4-hydroxy-cinnamic acid). The sample plate 
is loaded into the instrument, and mycobacterial proteins are ionized using a laser. The 
ionized proteins then move through the time of flight chamber and are separated based on 
the mass-to-charge ratio of the ions, such that the lighter proteins hit the detector first, 
followed by the heavier proteins. A mass spectrum is produced as the ions collide with 
the ion detector and serves as a ―fingerprint‖ for identification of the mycobacterial 
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species. Currently, there are two commercial MALDI-TOF platforms available for 
microbial identification, the Vitek®MS (bioMerieux,NC) and the Biotyper system 
(Bruker Daltonics,MA). Databases supplied with both instruments contain entries for 
many NTMs, including those most commonly encountered in the clinical laboratory. 
Recent studies have demonstrated the ability of MALDI-TOF mass spectrometry to serve 
as a rapid and accurate means for the identification of mycobacteria from both solid and 
liquid media(97–99).  
Advantages: According to a study using the latest version of the database, 94% of the 
mycobacterial isolates tested can be identified up to the species or complex level(100). 
Although the cost of MALDI-TOF mass spectrometry instrument is not insignificant, 
studies have shown that this technique has minimal associated reagent costs, requires 
minimal technologist time, can be utilized for a wide variety of microorganisms, and 
provides a reduction in turnaround time for organism identification, leading to an overall 
reduction in costs. 
Disadvantages:A potential limitation in comparison to molecular sequencing methods is 
the requirement for a moderate amount of growth present on solid media rather than the 
scant growth required for sequencing. This problem is most evident when identifying the 
slowly growing mycobacteria. (57) 
3.6.10 DNA SEQUENCING 
Gene sequencing is the reference method for the identiﬁcation of NTM species and may 
be performed for rare species or for precise identiﬁcation at the subspecies level. 
Sequencing of the 16SrRNAgene allows discrimination at the species level or to the 
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complex level, such as for MAC. However, single-target sequencing cannot be used to 
accurately differentiate species, and for a higher level of discrimination, up to the 
subspecies level, sequencing of several key targets, such as hsp65, rpoB, and the 16S-23S 
internal transcribed spacer, is required(101). 
16S rRNA sequencing:  
The 16SrRNA gene is composed of approximately 1,500 base pairs. It is a highly 
conserved gene composed of two major sequences known as regions A and B. For 
mycobacterial species identiﬁcation, partial sequencing of region A, which contains most 
of the species-speciﬁc sequence variations (―signature sequences‖), is often adequate, 
while region B maybe conﬁrmatory. This has been used to achieve rapid and accurate 
identification of the most common clinically relevant mycobacteria. After DNA 
extraction from culture, a PCR is performed using the specific primers. The sequence is 
then determined through capillary-based sequencing, and the product is submitted as a 
query to a genetic database that is maintained and updated by the manufacturer. All of the 
RGM (except for M. chelonae and the M.abscessus group, which each contain one copy) 
contain two copies of the 16S rRNA gene(101). Generally, members of the genus 
Mycobacterium are closely related to each other and may differ by only a few base pairs 
or none. However, differentiation of M. chelonae and M. abscessus and some species 
within the M. fortuitum group requires sequencing of 16S rRNA gene sites outside 
regions A and B. M. chelonae and M. abscessus differ by only 4 bp in the 16S gene, so 
complete 16S rRNA sequence analysis is required for species identiﬁcation unless other 
gene targets are sequenced(90,102). 
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ITS 1 Region sequencing: 
Another target is the internal transcribed spacer sequence, which separates the 16S and 
23S rRNA genes and is denominated ITS 1. The sequence of this fragment comprises 
only 200 to 330 bp and thus can easily be analyzed. Several sets of primers that enable 
the amplification and sequencing of the complete fragment have been published(103). 
For the ITS 1 sequence, a high variability that is used for species identification has been 
shown. Two or more sequence variants have been observedfor some species, mainly for 
rapidly growing species and occasional slowly growing species (M. simiae and M. 
xenopi). As with the 16S rRNA gene sequence, M. marinum and M. ulcerans have 
identical ITS sequences and thus cannot be differentiated by this analysis(57,104). 
hsp65 genesequencing: 
 The 65-kDa heat shock protein gene (hsp65) also has hypervariable regions, the 
sequences of which may be used for identiﬁcation to the species level. Like the hsp65 
PRA(PCR Restriction fragment Analysis), sequence analysis of this gene involves the 
same 441-bp segment (105). hsp65 is not as well-conserved as the 16S rRNA gene 
sequence. But it has proven useful for species-level identiﬁcation of closely related RGM 
isolates, such as M. abscessus and M. chelonae. These two species differ by only 3 of 
approximately 1,500 base pairs of the 16S rRNA gene, while they differ by almost 30 
base pairs in the 441-bp hsp65 gene. In addition, species such as M. fortuitum, M. 
septicum, M. peregrinum, M. houstonense, and M. senegalense are more readily 
discriminated by hsp65 gene analysis than by 16S rRNA gene analysis (92). As with all 
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gene sequencing methods, the integrity and updating of the database for hsp65 gene 
sequences remains the major limitation for this method(42). 
rpoB gene sequencing: 
The rpoB gene is a single-copy gene that encodes the β subunit of RNA polymerase and 
has been used recently in the identiﬁcation of RGM, including the identiﬁcation of 
several new species (106,107).Sequencing of the rpoB gene has an advantage over16S 
rRNA sequencing in that a single site without a deletion or insertion is usually small 
enough to be sequenced directly in both directions at one time and contains enough 
information to identify many of the RGM to the species level. Recent studies have shown 
that the complete rpoB sequences vary from 84.3% to 96.6% for most species, compared 
to a 95.7% to 99.7% variation by sequencing of the 16S rRNA gene(108).The most 
commonly used sequence for RGM is a 723-bp fragment in region V(106). Just as for 
other sequence databases, a sufﬁcient, updated, and quality-controlled database is 
necessary for accurate identiﬁcation of RGM to the species level. 
3.6.11 OTHER MOLECULAR TESTS FOR NTM 
Sequence analysis of target genes for the identification of mycobacteria may not be 
practical for routine clinical laboratories. Commercially available assays that are based on 
liquid- or solid-phase hybridization have been shown to be easily implemented into a 
routine workflow. They are intended for the detection of some of the most 
commonMycobacterium species and can be performed from both solid and liquid media. 
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Identification using AccuProbe- The AccuProbe test was the first commercial 
molecular assay for the identification of selected mycobacterial species from positive 
culture media. Probes are available for the identification of Mycobacterium tuberculosis 
complex, M. avium, M. intracellulare, MAC, M. gordonae, and M. kansasii. All probes 
are FDA cleared and commercially available. Species identification is based on the 
hybridization of specific DNA probes to rRNA of the bacteria. Briefly, by heat treatment 
and sonication, nucleic acids, including the target 16S rRNA, are released from the 
mycobacteria. A specific DNA probe hybridizes with the target rRNA. Finally, the DNA-
rRNA hybrid molecule can be detected by chemiluminescence. The results are obtained 
within 2 hours. The utility of these tests has been proven in many studies and by usage in 
many laboratories worldwide. Specificity of the test varies from 90-100% and sensitivity 
is nearly 100 % (109,110). 
Disadvantages: The probes are limited to a few, albeit important, mycobacterial species, 
necessitating the performance of additional tests for identification of species for which 
there are no probes. The need to perform individual tests for each target species renders 
the tests expensive and, if not performed in parallel, also time-consuming. Studies have 
also shown cross-reactions between the M. intracellulare probe andseveral other slowly 
growing mycobacterial species(57). 
3.7 DRUG SUSCEPTIBILITY TESTING 
Drug susceptibility testing (DST) for NTM is difﬁcult and controversial because of 
discrepancies between in vitro susceptibility and in vivo clinical outcomes. The gold 
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standard method for DST of NTM is broth microdilutionperformed according to a 
standardized protocol from the Clinical and Laboratory Standards Institute. The 
Minimum Inhibitory Concentration (MIC), expressed in µg/ml,have been determined 
using concentrations derived from serial twofold dilutions indexed to base 1 (e.g., 1, 2, 4, 
8, 16, and 32 µg/ml). It represents the ―true value‖ which is the closest agreement 
between the average value obtained from a large series of test results and an accepted 
reference value. The ―true value‖ is somewhere between the lowest test concentration 
that inhibits the growth of organism (i.e. MIC reading) and the next lower test 
concentration(111).  
For slowly growing NTM such as MAC, macrolide susceptibility testing, specifically 
clarithromycin is recommended as the class agent for DST. Macrolide resistance in MAC 
is caused by mutations in the macrolide binding site of 23S rRNA. Rifampin and 
clarithromycin are the currently recommended drugs for primary susceptibility testing for 
M. kansasii. DST reading is taken at 10- 14 days, if growth controls are satisfactory. 
For rapidly growing mycobacteria, the agents that should be tested are amikacin, 
cefoxitin, ciproﬂoxacin, clarithromycin, doxycycline (or minocycline), imipenem, 
linezolid, moxiﬂoxacin, trimethoprim-sulfamethoxazole, and tobramycin. Readings of 
DST is taken at 3-5 days, provided the growth controls are satisfactory. 
Inducible macrolide resistance to clarithromycin is observed during in vitro DST after 
prolonged incubation (susceptible at day 3 but resistant at day 14) or after preincubation 
in macrolide-containing media. Therefore,it is recommended that the ﬁnal reading for 
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clarithromycin be performed after at least 14 days. This inducible resistance to 
clarithromycin is due to a functioning erythromycin ribosomal methylase erm(41) gene, 
which is present in most strains of M. abscessussubsp. abscessus but not in M.abscessus 
subsp. massiliense(111,112). 
3.8 MANAGEMENT OF NTM DISEASES 
A diagnosis of NTM lung disease does not necessitate the initiation of antibiotic therapy 
against NTM species (1). Instead, this decision should be made based on the potential 
risks and beneﬁts for individual patients of a prolonged course of treatment with multiple 
antibiotics. Initiation of NTM treatment should be individualized based on disease type, 
comorbid conditions, and age Once the decision has been made to initiate treatment for 
NTM lung disease, the treatment regimen should be formulated according to established 
guidelines, understanding that a substantial proportion of the current guidelines rely upon 
expert opinion rather than randomized clinical trials. However, adherence to the current 
guidelines for treating NTM lung disease is poor (44,111). 
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Table 11. Management of NTM diseases 
Clinical presentation Species Treatment 
Pulmonary disease 
 
MAC  Macrolide, rifamycin, ethambutol daily or three times a week 
(t.i.w) ± streptomycin/amikacin t. i. w 
M. kansasii  Rifampin, ethambutol, isoniazid daily or rifampin, macrolide, 
ethambutol daily or t. i. w 
M.simiae  No regimen with good clinical data on efficacy 
M.abscessus (subsp. 
abscessusand bolletii) 
 Three or four of the following: amikacin, cefoxitin, imipenem, 
tigecycline, linezolid, macrolide (macrolides may be inactive if 
erm gene is functional) 
M. abscessus subsp. 
massiliense 
 Macrolide plus two of the following: amikacin, cefoxitin, 
imipenem, linezolid 
M. szulgai, M. 
malmoense,M. xenopi 
 
 Same as MAC regimen 
Adapted from British Thoracic Society guidelines for the diagnosis and management of NTM-PD, 2017(35,81) 
For patients with pulmonary disease, treatment is continued for at least 12 months after sputum cultures become 
negative(44).  
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Table 11.  Management of extrapulmonary and disseminated NTM infections  
Clinical presentation Species Treatment 
Cervicofacial 
lymphadenitis 
MAC  Surgical excision was more effective than antibiotic therapy (cure rate 
of 96% vs 66% for a 3-month regimen of rifabutin- clarithromycin) 
Disseminated- at least 
for 12 months of 
therapy 
MAC (if macrolide 
susceptible) 
 Macrolide, rifamycin, ethambutol daily or t.i.w  
 i. v aminoglycosideduring the initial 8 to 12 weeks of therapy 
 MAC (if macrolide 
resistant) 
 Ethambutol plus rifabutin plus an aminoglycoside (parenteral) 
 Surgical intervention (e g, valve replacement, joint replacement, or 
debridement of infected bone) if required 
   M. chimaera  Macrolide, rifamycin, ethambutol daily or t.i.w 
Disseminated RGM 
infections 
  No evidence-based treatment available 
 Surgical debridement wherever possible 
plus 4 months of two-drug antibiotic treatment based on susceptibility 
test results 
   M. fortuitum complex 
 
M. abscessus 
 Combination of quinolones, co-trimoxazole, tobramycin, doxycycline 
and imipenem 
 Amikacin, imipenem, cefoxitin, linezolid and macrolides(if no 
functional erm gene) 
References: (113–115) 
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4.MATERIAL AND METHODS 
4.1 STUDY DESIGN 
This is a prospective diagnostic studyconducted for a period of 21 months. 
4.2 ETHICAL APPROVAL 
The approval for conducting the study was obtained from the Institutional Review Board, 
Christian Medical College, Vellore 
4.3 STUDY DURATION 
The study was conducted for a period of 21 monthsfrom January 2017 to September 
2018. 
4.4 STUDY SAMPLES 
NTM isolates cultured from clinical samples received at the Department of Clinical 
Microbiology for mycobacterial culture/ culture and drug susceptibility testing. 
4.5 SAMPLE SIZE CALCULATION 
Sample size was taken as 90 as this is a pilot study since the exact prevalence of NTM 
diseases in our setting is not known. 
4.6 DATA SOURCE 
Relevant clinical data regarding the clinical isolate was obtained from electronic patient 
records (Clinical work station) of the institution. 
 
4.7STUDYALGORITHM 
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4.8CONVENTIONAL TESTS 
Samples are cultured on Lowenstein Jensen media (solid) or Middlebrook 7H9 broth in 
BACTEC Mycobacterial Growth Indicator Tube (MGIT) 960 automated system as per 
the treating clinician‘s request. The optimal temperature for growth of most NTMspecies 
is between 28°C and 37°C. Positive MGIT cultures are sub cultured on LJ media. 
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The culture growth on LJ should be examined after 3 and 7 days and weekly thereafter 
for 6 to 9 weeks. Cultures that show visible colonies on LJ media are taken for further 
identification. 
Figure 5. Phenotypic features for identification of NTM from LJ media: 
 
 
 
 
 
 
 
3. Pigment production
Photochromogens Scotochromogens Non-chromogens
1.2. Rate of growth 
Slowly growing NTM- takes 7 days or 
more for growth on LJ medium
Rapidly growing NTM- grows within 7 
days on LJ medium
1.1. Cultural characteristics
Smooth colony 
morphology
Emulsify easily in saline 
suspension
Negative on MPT 64 
Immunochromatographic 
test
66 
 
Figure 6. Classification based on pigment production 
 
3. Biochemical tests 
Table 11. Common biochemical tests 
Test Principle Result Observation 
Nitrate 
reduction 
test 
Nitratereductase enzyme 
reduces nitrate (NO3
–
) to 
nitrite (NO2
–
) or free 
nitrogen gas 
 
Positive: medium turns 
red after the addition of 
nitrate reagents  
Negative: medium 
turns red after the 
addition of the zinc 
 
 
i.Photochromogens: 
produce a pigment 
only on the slopes 
exposed to light. Eg: 
M. kansasii
Scotochromogens: 
produces pigment both 
in the presence and 
absence of light.
Eg: M. gordonae
Non-chromogens: 
does not produce 
pigment in the 
presence or absence of 
light. Eg: M. 
avium, M. fortuitum
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Arylsulfatase 
test 
 
Arylsulfatase hydrolyzes 
the bond between the 
sulfate and the aromatic 
rings of tripotassium 
phenolphthalein 
 
Positive: pink colour 
when alkali is added to 
the medium 
Negative: colourless 
 
 
Test for 
urease 
production 
Ureaseenzymesplit urea in 
the urea broth into 
ammonia resulting in 
alkalinity 
Positive: media turns 
pink colour 
Negative: media 
remains yellow in 
colour 
 
Test for 
tellurite 
reduction  
 
To determine the ability of 
Mycobacterium spp. to 
reduce potassium tellurite 
to metallic tellurium 
Positive:Black 
precipitate around the 
colonies or the solution  
Negative: no black 
precipitate 
 
 
Slow growers are differentiated in the lab using tellurite reduction, nitrate reduction, 
tolerance to LJ with 5% NaCl and urease production tests. 
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Figure7. Algorithm for biochemical identification of common slow growers. 
Rapid growers are identified in the lab by arylsulfatase activity (at 3 days), nitrate 
reduction, tolerance to LJ with 5% NaCl. 
 
 
Colony morphology
Chromogens:
M.kansasii,M.gordonae
M.simiae
Nitrate reduction
Positive:
M.kansasii
Negative:
M.simiae,M.gordonae
Urease-positive
M. simiae
Urease- negative
M.gordonae
Non-chromogen:
M.avium complex - Tellurite
reduction positive
Nitrate  positive
Growth on 5% NaCl-
negative
Arylsulfatase activity
Positive:
M.fortuitum,M.chelonae,M.abscessus
Nitrate reduction
Positive:
M.fortuitum
Negative:
M.chelonae,M.abscessus
Growth on 5% NaCl-
positive-M. abscessus
Growth on 5% NaCl-
negative-M.chelonae
Negative:
M.smegmatis
Nitrate  positive
Growth on 5% NaCl-
negative
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Figure 7. Algorithm for biochemical identification of common rapid growers. 
Table 12.Conventional method of NTM species identification using biochemical 
tests: 
Slow growers: MPT 
64 
Tellurite  
reduction 
Nitrate 
reduction 
Tolerance 
to 5% 
NaCl 
Urease Aryl 
Sulfatase 
activity 
M. kansasii - + + - + - 
M. marinum - + - - + V 
M. simiae -  + - - + - 
M.scrofulaceum - + - - + - 
M. szulgai - + + - + - 
M. gordonae - - - - - - 
M. avium 
intracellulare 
complex 
- + - - - - 
M. malmoense - + - - - - 
M. xenopi - +/- - - - + 
Rapid 
Growers: 
      
M.smegmatis - + + + Not 
done 
- 
M. fortuitum - + + + -do- + 
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M.chelonae - - - - -do- + 
M.abscessus - - - + -do- + 
 
4.10 Line probe assay: 
The line probe assay used for identification of NTM species in this study is Genotype 
Mycobacterium CM (VER 2.0) (Hain Lifescience).  
Principle: LPA is based on solid phase reverse hybridization of biotinylated PCR 
amplicons of the target region to oligonucleotide probes arranged on a membrane strip. 
Methodology:  
The whole procedure is divided into three steps: DNA extraction (from positive cultures); 
a multiplex PCR amplification with biotinylated primers and reverse hybridization. 
DNA extraction: Mycobacteria grown on the solid culture media is used as the starting 
material. DNA is extracted using the GenoLyse® kit. 
Amplification:Following DNA extraction, nucleic acids are selectively replicated in an 
amplification reaction using the amplification mix-A and B in the thermal cycler. 
Reverse hybridization: 
1. The hybridization buffer was prewarmed to 50
o
c in a water bath.  
2. Transfer 20 µl of denaturing solution to the wells and add 20 µl amplified product. Mix 
well and incubate for 5 min. 
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3. Add 1ml of hybridization buffer to each lane and this was mixed to make 
homogeneous colour.Place the strips in respective wells. 
4. The program P3S1(GT FAST) is used on the Twincubator. The machine is set at Step 
1(20 minutes, shaking at 50
o
C), while the stringent solution is warmed in a water bath to 
a temperature of 50
o
C. 
5. The hybridization buffer was aspirated completely with pipette and tapped onto tissue 
paper. 
6. Add 1 ml of stringent solution to each lane. The Twincubator was set to Step 2 (10 
minutes, shaking at 50
o
C). 
7. Aspirate the stringent solution completely with a pipette and taponto tissue paper and 
add 1 ml of conjugate solution. 
8. Step 3 (20 minutes, shaking) is set up in Twincubator.  
9. Remove the conjugate completely by tapping off onto tissue paper 
10. One ml of Rinse solution is added and the step is selected in the Twincubator (1 
minute, shaking). 
11. One ml distilled water is added and the washing step is selected in the Twincubator (1 
minute, shaking). Remove the water completely by tapping off onto tissue paper. 
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12. One ml of substrate solution is added to each lane and placed in the Twincubator (5-
10minutes, stationary). Cover the Twincubator with aluminium foil till the substrate 
incubation is over. 
13. The substrate is removed completely and tapped off onto tissue paper. 1 ml distilled 
water is added. The water is removed completely and tappedoff onto tissue paper. 
14. The strips were stuck on the evaluation sheet while wet and results interpreted as per 
Genotype® Mycobacterium CM interpretative chart. 
4.10.3 MALDI-TOF 
Principle: Mass spectrometry is an analytical technique in which samples are ionized 
into charged molecules and ratio of their mass-to-charge (m/z) can be measured. It is the 
ionization that involves a laser striking a matrix of small molecules to make the analyte 
molecules into the gas phase without fragmenting or decomposing them. The basic 
principle of time-of-flight is that ions of different m/z are dispersed in time during their 
flight along a field-free path of known length. Provided that all the ions start their journey 
at the same time, the lighter ones will arrive earlier at the detector than the heavier ones. 
Procedure: Performed in BSL III laboratory till the inactivation step. 
Protein extraction- 
1. For each organism to be tested, transfer 0.5mL of ethanol to a tube with glass beads. 
2. Use a 1 µL loop to pick up and transfer two loopful of the test organism to the tube. 
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3. Homogenize the organism in a bead beater for 5minutes at 6.5 meter/second. 
4. Remove the screw capped tube from bead beater and incubate it at room temperature 
for 10 minutes.  
5. Vortex for 5 to 10 seconds and immediately transfer suspension into an empty 2 mL 
round-bottomed tube using a pipette and avoiding transfer of any glass beads.  
6. Centrifuge sample for 2 minutes at 14,000 G to create a pellet.  
7. Discard all the supernatant ethanol using a pipette. 
 8. Add 10 µL of formic acid to the pellet. Vortex it for 5 seconds. 
9. Add 10 µL of acetonitrile and mix using a vortex for 5 seconds.  
10. Centrifuge for 2 minutes at 14,000 G to create a pellet. 
11. Transfer 1.5 µL of the supernatant onto the target slide spots. Allow each spot to dry 
completely.  
12. Add 1 µL of α-cyano-4-hydroxycinnamic acid(matrix) to each target slide spot. 
Allow matrix to dry.  
Target slides were kept at room temperature and analyzed using Vitek®MS v3.0, which 
includes amass spectrometer linked to a reference database. Laser shots are targeted at 
different positions within the sample well which will produce up to 100 mass profiles of 
protein that are summed into a single, raw mass spectrum. 
74 
 
 
Figure 8. Mass spectra of an NTM isolate 
The spectrum is then processed by baseline correction, de-noising, and peak detection to 
identify the well-defined mass/charge peaks.Spectra are then acquired and analyzed using 
Myla 4.0 software with database version 3.0. 
 
Figure 9. Result of NTM species identification by MALDI-TOF 
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4.11 INDEX TEST- DNA SEQUENCING 
DNA sequencing is the term which refers to methods for determining the order of the 
nucleotide bases adenine,guanine,cytosine and thymine in a molecule of DNA. 
Sanger sequencing: 
The key principle of the method is the use of di-deoxynucleotide triphosphates (ddNTPs) 
as DNA chain terminators. 
STEP 1: DNA EXTRACTION FOR SEQUENCING: 
1. Pure culture of the NTM from Lowenstein Jensen media (solid media) is selected. 
2. Emulsify one or two loopful of the culture in 200 microliters of sterile normal 
saline taken in an Eppendorf tube.Pulse vortex for 15 seconds. 
3. Add 100 microliter of Lysozyme. Pulse vortex for 15 seconds.Incubate at 37oc for 
1 hour. 
4. Add 20 microliter of Proteinase K. Pulse vortex for 15 seconds. Incubate at 56oc 
for 30 minutes. 
5. Add 200 microliter of Alkaline Lysis(AL) buffer. Pulse vortex for 15 seconds. 
Incubate at room temperature for 10 minutes 
6. Add 250 microliter of 99.9% Ethanol. Pulse vortex for 15 seconds. 
7. Transfer the whole content to a DNA spin column without touching the rim. Avoid 
air bubbles.Centrifuge at 8000 rpm * 1 minutes 
8. Discard the collection tube with the flow through.Take a new collection tube. 
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9. Add 500 microliter of Wash buffer 1(AW1). Centrifuge at 8000 rpm x 1 minutes. 
Discard the flow through. 
10. Add 500 microliter of Wash buffer 2(AW2). Centrifuge at 14000 rpm x 3 minutes. 
Discard the flow through. 
11. Centrifuge at 10000 rpm x 1 min (Dry spin). Place a new collection tube 
12. Add 100 microliter of Elution Buffer. Keep it at Room temperature for 5 minutes. 
13. Centrifuge at 8000 rpm x 2 minutes. 
14. Transfer the eluate into another Eppendorf tube. Label it properly. Store the DNA 
at -20
o
c. 
Step 2: DNA Quantification: 
For quantitating DNA or RNA, readings should be taken at wavelengths of 260 nm 
and 280 nm. The reading at 260 nm allows calculation of the concentrate on of 
nucleic acid in the sample. The reading at 280 nm gives the amount of protein in the 
sample. 
 DNA quantification [in nanogram/µl] is given by the following formula 
=Absorbance at 260 nanometer (OD260) x 50 nanogram/ µl x 10 (dilution factor)  
For Sanger sequencing the DNA concentration of 20-25 nanogram/ µl is ideal.DNA 
purity can be identified dividing the readings at 260 by reading at 280 (nm). Pure 
preparations of DNA should have OD260 /OD280 values of 1.8. If there is 
contamination with protein or phenol, this ratio will be significantly less than the 
values given above, and accurate quantitation of the amount of nucleic acid will not 
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be possible. Once the DNA quantification is satisfactory, the extraction product can 
be used for sequencing. 
Step 3: Conventional PCR (Polymerase Chain Reaction) for amplifying the 
targetDNA: 
In this study, two targets are used for sequencing- 16S rRNA and Internal 
TranscribedSpacer (ITS) region 
16S rRNA primer sequence:Universal 16S rRNA primers first described by Turner 
etal was used for the sequencing(116) 
16S rRNA Forward: 5ˈ-AGAGTTTGATCCTGGCTCAG-3ˈ 
16S rRNA Reverse: 5ˈ-ACGGTTACCTTGTTACGACTT-3ˈ 
ITS primer sequence:Reference: Yu et al, PloS,2014(117) 
ITS-Forward (16SrRNA)- 5‘-GTGGGATCGGCGATTGGGAC-3‘ 
-  positions 1280 to 1299 of the 16S rRNA gene 
ITS-Reverse (23SrRNA)- 5‘- CCACCATGCGCCCTTAGACAC -3‘  
- positions 7 to 27 of the 23S rRNA gene 
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Gel documentation after conventional PCR: 
(a)                                 (b)  
Figure10. a. Gel picture of 16S rRNA PCR- Product size approximately 1500 bp. 
b. Gel picture of ITS region PCR- Product size approximately 350 bp 
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Pre-sequencing clean up 
1. Add 5 volumes of PB(Binding) buffer to 1 volume of the PCR reaction and transfer to 
QIAquick
TM
 column.Centrifuge at 13000 rpm for 1 minute and discard the flow through. 
2. Add 750 µl of PE(Ethanol) buffer, Centrifuge at 13000 rpm for 1 minute and discard 
the flow through. 
3. Centrifuge at 13000 rpm for 1 minute to remove residual wash buffer. 
4. Place a new 1.5ml micro centrifuge tube then add 50µl of elution buffer in the center 
of the QIAquick
TM
 membrane and centrifuge 13000rpm for 1minute. 
5. The purified DNA is to be analyzed on a gel and add 1 volume of loading dye to 5 µl 
purified DNA.Check the quantification of DNA by using spectrophotometry. 
SEQUENCING PCR REACTION: The reagents required for one PCR reaction include 
ready reaction (RR) mixture 0.5 µl, sequencing buffer 1.75 µl, primer 0.5 µl and milli Q 
water 6.25 µl.Add 1 µl of DNA template to the above to make the total volume of 10 µl  
and load into thermal cycler. 
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Post clean up 
Procedure 
1. Transfer the reaction product into a 1.5 ml micro centrifuge tube. 
2. Make a master mix of 1 of 10 µl Milli-Q and 2 µl of 125 mM EDTA per reaction. 
3. Add 12 µl of master mix I to each reaction containing 10 µl of reaction. Make sure the 
contents are mixed. 
4. Make master mix II of 2 µl of 3M Sodium acetate (NaOAc) pH 4.6 and 50 µl of 
ethanol per reaction. Add 52 µl master mixes II to each reaction. 
5. Mix the content well and incubate at room temperature for 15 minutes. 
6. Spin at speed of above 12000rpm for 20 minutes at room temperature and discard the 
supernatant. 
7. Add 250 µl of 70 % of ethanol and spin at above 12000 rpm for 10 minutes at room 
temperature and discard the supernatant. 
8. Add 12-15 µl of Hi-Di formamide, transfer to sample tube cover with septa, denature 
snap chill and proceed for electrophoresis. 
The DNA fragments on each strand will be sequenced with the primers used in the initial 
PCR amplification by using the ABI PRISM BigDye Terminator Cycle Sequencing kit 
V3.1 (Applied Biosystems, USA) and the sequencing was carried out on the ABI 3500 
Genetic Analyzer (Applied Biosystems, USA). 
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Sequence analysis  
First, merge the raw sequences of forward and reverse primers in EMBOSS merger to get 
the double stranded DNA information. The resulting sequences were BLAST matched 
against the reference sequences in the NCBI database. 
 
Figure 12. Chromatogram of the DNA sequence 
 
Figure 13. BLAST(Basic Local Alignment Search Tool) analysis of the sequence using 
NCBI Genbank® database (https://blast.ncbi.nlm.nih.gov/)  
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5. RESULTS 
A total of 90 consecutive clinically significant NTM isolates were included in the study. 
These were isolated from samples that were received in the laboratory for routine 
mycobacterial diagnosis between January 2017 and September 2018.  
5.1 Demographic data: 
5.1.1 Age: The samples belonged to patients aged between 0 to 74 years. Highest number 
of samples were received from patients in the 41 to 50 years age group. The mean age 
was 42 years. 
 
Figure 14. Age-group wise distribution 
5.1.2 Gender: Of the 90 patients, 50 (56%) were male and 40 (44%) were female. 
5.1.3 Geography:   The patients in this study came from different parts of India and also 
from neighboring countries Bangladesh and Nepal. Majority of them came from Tamil 
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Nadu (25, 28%), West Bengal (23, 26%), Jharkhand (12, 13%) and Andhra Pradesh 
(11%).
 
Figure 15. Geographic distribution of patients 
5.2 Clinical specimen 
Of the 90 isolates, 50 were isolated from the respiratory tract- sputum (39 samples), 
bronchoalveolar lavage (8 samples), lung biopsy (2 samples) and endotracheal aspirate (1 
sample). 
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Figure 16. Sample distribution 
5.3 Non-Tuberculous Mycobacterial species identification 
In this study, out of the 90 isolates, 49 (54%) were slow growers and 41 (46%) were 
rapid growers.  
Based on 16S rRNA sequencing, which is the gold standard, they were identified up to 
the species level. 
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5.3.1 Slowly growing NTM species 
The most common slow growingNTMs isolated in this study were M. intracellulare 
(19/90, 21%) followed by M. simiae (8/90, 8.8%)and M. avium (6/90, 6.6%). Species 
with intermediate growth rate such as M. flavescens and M. novocastrensehave been 
included along with slow growers in this study. As shown in the figure below the other 
slow growing NTM species identified were M. avium complex, M. kansasii, M. szulgai, 
M. yongonense, M. timonense, M. scrofulaceum, M. parascrofulaceum and M. 
europaeum. 
One isolate which could only be speciated upto genus level by 16S rRNA sequencing was 
identified as M. europaeum by ITS sequencing. 
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Fig 17. Slowly growing NTM species 
5.3.2 Rapidly growing NTM species 
The most common rapidly growing NTM isolated in this study were M. abscessus (n=26, 
63%) followed by M. fortuitum (n=10, 24%). Other species isolated were M. 
farcinogenes, M. bacteremicum, M. phocaicum and M. goodii. 
 
Figure 18. Rapidly growing NTM species 
5.4 Clinical presentationof slowly growing NTM: 
Pulmonary disease: The most common clinical form of disease caused by slowly 
growing NTM isolated in this study was pulmonary disease. Of the 49 patients who 
presented with NTM pulmonary disease, 40 (81.6%) were due to slow growers. Among 
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these isolates, 17 were M. intracellulare, 7 were M. simiae, 3 were MAC (which were 
identified as M. intracellulare by ITS sequencing), M. avium, M. kansasii and M. 
europaeum were 2 each by 16S rRNA sequencing. Other rare species like M. timonense, 
M. yongonense, M. szulgai, M. parascrofulaceum and M. scrofulaceum were isolated 
from 1 patient each. Two NTMs isolated from sputum were not clinically significant and 
were possible colonizers and it was identified as M. flavescens and M. longobardum. 
Twenty-five patients (25/50= 50%) had past history of tuberculosis and twenty (20/50= 
40%) of them had associated bronchiectasis. 
Disseminated infection: This was the second most common presentation of slow 
growers. Seven patients had disseminated infections with M. avium (isolated from 4 
patients), M. intracellulare (2 patients) and M. simiae (1 patient), isolated from bone 
marrow and lymph node specimens. Six (86%) of these patients had acquired immune 
deficiency syndrome (AIDS) with CD4 cell count less than 150 cells/µl at the time of 
diagnosis. Median CD4 count of these patients was 124 cells/µl. 
One patient was 3 years old with Severe Combined Immunodeficiency Disorder (SCID) 
from whom M. avium was isolated from the middle ear tissue biopsy.  
Skin and soft tissue infections: There were no patients who presented with skin and soft 
tissue infections associated with slow growers in this study. 
Contaminants:M. novocastrense and M. flavescens were isolated from bone marrow 
biopsy and urine sample respectively, which were considered to be contaminants as there 
was no clinical signs or symptoms consistent with NTM disease. 
88 
 
 
Figure 19. Clinical spectra of slowly growing NTMs 
5.5 Clinical presentationof rapidly growing NTM: 
Skin and soft tissue infections: The predominant clinical manifestation due to rapidly 
growing NTMs were skin and soft tissue infections (16/41 =39%). Most of them were 
due to post- operative wound infections (9/16, 56%), with inguinal hernia repair with 
mesh placement being the predominant type of surgery associated with the disease (3 
cases). Other surgeries implicated were laparotomy, laparoscopic surgeries of abdomen 
and caesarean section. Two patients presented with injection site abscess. Other clinical 
presentations were breast abscess, skull base osteomyelitis, abscess at chemotherapy port 
site, traumatic injury to the flexor zone and discharging sinus (in one patient each). 
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Twelve out of the 16 cases were due to M. abscessus, 3 were caused by M. fortuitum and 
1 by M. farcinogenes. 
Blood stream infection/ line associated infections: M. abscessuswas associated with 7 
cases of blood stream infection. The patients who were admitted in the hospital for more 
than 2 weeks, who had various risk factors like presence of central venous line, invasive 
procedures done on the cardiovascular system (stent, valve repair) and therapy with 
immunosuppressants for haematological malignancies or treatment with 
immunomodulators for disorders of immune system were the ones that presented with 
NTM bacteremia. M. fortuitum and M. phocaicum was identified from one case of blood 
stream infection each. 
Pulmonary infections: Rapid growers were isolated from respiratory samples of 9 
patients. M. fortuitum was isolated in 5 patients, out of which only 3 were clinically 
significant. M.abscessus was isolated from the samples of 4 patients from multiple 
samples from the same patient. One of them was an infant with lipoid pneumonia who 
succumbed to the infection. 
Ocular infections: Two patients who had the history of corrective eye surgery for 
strabismus and cataract surgery presented with ocular infections with M. abscessus. 
Infections of the urinary tract: M. abscessus was isolated from 2 patients. One of them 
had past history of genitourinary tuberculosis and the other had previous surgery with 
ureteric stent placement. 
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Rare presentations:M. mucogenicum was isolated from the bone marrow biopsy of a 
patient with history of pyrexia of unknown origin of 4 weeks duration. 
 
Figure 20. Clinical spectra of rapidly growing NTMs 
5.6 Laboratory data 
5.6.1 MALDI TOF identification 
MALDI-TOF mass spectrometry was performed on all the 90 isolates. It could identify 
75 of the 90 isolates up to species or complex/group level. It could not identify 13(13/90= 
14%) isolates, out of which 11 were slow growers. Two isolates were wrongly identified 
as non-mycobacterial species. As mentioned in table 13, the concordance of MALDI-
TOF with the gold standard 16S rRNA sequencing was 83.33%. 
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5.6.2 Internal transcribed spacer (ITS) sequencing 
ITS sequencing was performed on all the slow growers and M. avium was identified upto 
subspecies level. Out of the 6 Mycobacterium avium isolates, all were identified as M. 
avium subsp. hominisuis. The results were compared with 16S rRNAsequencing and 
MALDI-TOF as described in the table 15 below. 
5.6.3 Concordance 
Table 15. Concordance between the results of 16S rRNA sequencing, ITS 
sequencing and MALDI-TOF 
Tests compared 
(Total tests, n=90) 
Concordance 95% confidence interval 
16S rRNA sequencing vs 
MALDI TOF 
 For rapid growers 
 For slow growers 
83% (cumulative) 
 
94.5% 
77.5% 
74.00- 90.4% 
 
81.3- 99.4% 
63.9- 81.4% 
16S rRNA sequencing vs 
ITS sequencing 
95.5% 82.4- 99.7% 
ITS sequencing vs MALDI-
TOF 
76% 63.9- 81.4% 
 
5.7 Cost analysis 
5.7.1 Particulars for costing of Sanger sequencing 
Table 16. Sanger's sequencing cost per DNA sample   
a. Material cost (chemicals and reagents)-  INR 
DNA extraction per sample 250 
Reagent kit with RR mix for testing two DNA targets- 16S rRNA 3000.00 
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and ITS (Applied Biosystems) (@Rs.1500/- per target) 
b. Consumables   
1. Gloves 5 sets (@ Rs. 20/- per set) 100.00 
2. Pipette tips 50 Nos. (@Rs.2.90 each)  145.00 
3. Pipettes (1000 µl, 100 µl, 10 µl) 15.00 
4. Discard Lotion (@Rs. 50/-) 50.00 
5. Eppendorf tubes (@Rs. 1.5/- per tube) 11.50 
6. PCR tubes (@Rs. 0.5/- per tube) 2.00 
  323.50 
Total for one gene 3573.50 
 
5.7.2 Particulars for costing of MALDI-TOF mass spectrometry 
Table 17. MALDI-TOF cost per sample   
a. Material cost (chemicals and reagents)-  INR 
1.Protein extraction per sample (Rs 46000 / 100 tests) 460.00 
2. VITEK®MS-DS slide-1 spot  100.00 
3. VITEK®MS CHCA matrix- 1µl 10.00 
b. Consumables   
1. Gloves 2 sets (@ Rs. 20/- per set) 40.00 
2. Pipette tips 10 Nos. (@Rs.2.90 each)  29.00 
3. 1 µl disposable loop-2 no. s 7.00 
Total for one sample (exclusive of tax) 646.00 
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6 DISCUSSION 
Non-tuberculous mycobacteria (NTM) are a group of more than 190 species of 
mycobacteria apart from Mycobacterium tuberculosis complex and Mycobacterium 
leprae. They are an important public health concern worldwide as the cause of 
opportunistic infection, particularly in patients having acquired immunodeficiency 
syndrome and those on iatrogenic immunosuppression(118). 
According to the American Thoracic Society (ATS)/Infectious Diseases Society of 
America (IDSA) statement of 2007, when NTM are suspected as the etiology of disease, 
deﬁnitive diagnosis should always be supported by repeated isolation of NTM from two 
or more specimens of the patient or a single specimen if it is collected aseptically from a 
sterile body site(44). The British Thoracic Society guideline of 2017 also recommends 
that NTM should be identiﬁed to the species level using validated molecular or mass 
spectrometry techniques as the treatment is species-specific and pathogens must be 
distinguished from environmental contaminants(35). Thus, timely and accurate 
identification of NTM is required to guide therapy (patient outcome) and for 
epidemiological reason. 
For many years, the classiﬁcation developed by Runyon was utilized in clinical 
laboratories to provide a convenient way to differentiate among NTM based on the rate of 
growth of the and pigment production(23). However, it could not identify NTM upto the 
species level. Speciation of clinically isolated NTMin the laboratory was initially 
performed using an array of biochemicals and later with High Performance liquid 
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chromatography (HPLC) and then in recent years with Line probe assays. All three had 
limited utility as they were restricted to identification of the most frequently isolated 
NTM species(42). Due to this, molecular sequencing of 16Sr RNA and Internal 
Transcribed Spacer (ITS) regions were developed, which will not only give an accurate 
identification but also be able to identify novel species. However, the high cost of the 
technique limits its use for routine diagnostics. Therefore, a novel technology called 
Matrix Assisted Laser Desorption/Ionization -time of flight (MALDI-TOF)was 
introduced, which is a simple, rapid, less expensive (after the initial purchase of the mass 
spectrometry instrument) and accurate method of identifying the NTM species using 
mass spectrometry of proteins. This method identifies organisms based on the creation of 
a unique species-specific spectral profile (fingerprint) produced by extracted ribosomal 
proteins with specific mass to charge ratios. Hence, we have compared the 16S rRNA 
(gold standard) and ITS sequencing with MALDI-TOF (index test) for the accurate 
identification of NTM species(100). 
6.1 Demographic data 
6.1.1 Age and gender: 
Unlike M. tuberculosis, NTM associated with human disease is not reportable in most 
countries, including India. Hence, the exact age and gender distribution is not known. In 
our centre, as depicted in figure no.14, highest number of patients with NTM disease 
were in the 41 to 50 years age group (22%). A study by Umrao et.al from north India 
found that patients of age more than 55 years were predominant (36.2%) in their setting.  
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Out of the 90 patients included in this study, 50 (56%) were male and 40 (44%) were 
female. This data correlates with a study conducted by Jesudason et.al at a tertiary-care 
centre from Vellore, south India(33). However, a multi-centric study from United States 
by Prevots et.al showed a higher prevalence in women when compared with men (1.1 to 
1.9-fold higher)(119). 
6.1.2 Geographic distribution 
Since the study was done at a tertiary-care hospital in South India, majority of the 
patientswere from Tamil Nadu (25/90= 28%) and Andhra Pradesh (10/90=11%). There 
were a considerable number of patients from north Indian states such as West Bengal 
(23/90= 26%), Jharkhand (12/90= 13%), Bihar (4/90= 4.4%) and Chattisgarh (2/90= 
2%); neighbouring countries like Bangladesh (6/90= 6%) and Nepal (1/90= 1.1%).  
6.2 Clinical specimen 
In this study, NTM were isolated from 50 (55%) pulmonary samples, sputum being the 
most common sample and 40 (45%) extrapulmonary samples as depicted in Figure 16. 
However, according to the population based laboratory surveillance in Oregon, United 
States, there was a significantly higher number (80–85%) of NTM pulmonary 
disease(120). In a study from north India by Umrao et.al, total of 79.4% of the NTM were 
recovered from pulmonary and only 18.2% from extrapulmonary samples(34). 
 
 
96 
 
6.3 Species identification 
Distribution of NTM species that are isolated from clinical samples differs strongly by 
region.In this study, out of the 90 isolates, 49 (54%) were slow growers and 41 (46%) 
were rapid growers. We used 16S rRNA sequencing as the reference standard for species 
identification. 
6.3.1 Slow growers 
Thirteen species of slow growers were identified from the samples included in this study. 
M. intracellulare (19/90= 21%) was the predominant species followed by M. simiae 
(8/90= 8.8%)and M. avium (6/90= 6.6%). As depicted in figure 17, the other slow 
growing NTM species identified were M. kansasii, M. szulgai, M. yongonense, M. 
timonense, M. scrofulaceum, M. parascrofulaceum, M. europaeum, M. flavescens and M. 
novocastrense. This is similar to the study conducted in north India by Umrao et.al, in 
which M.intracellulare and M.aviumwere the most common slow growers isolated(34).  
6.3.2 Rapid growers 
Seven species of rapid growers were isolated in this study as shown in figure 18, with M. 
abscessus being the most common (26/90= 28.8%). Other species were M.fortuitum 
(10/90= 11%), M. farcinogenes, M. phocaicum, M. mucogenicum, M. bacteremicum and 
M.goodii. Data from India, USA and multi-national studies by NTM-NET also reported 
M. abscessus to be the most pathogenic rapidly growing NTM to humans(34,121,122). 
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6.4 Clinical presentation 
6.4.1 Clinical presentation of slow growers 
The predominant clinical presentation of slow growers in our setting during the study 
period was pulmonary disease. Among the 49 pulmonary isolates in this study, 40 
(81.6%) were slow growers. Most common slowly growing NTM species isolated were 
M. intracellulare (17/49= 34.6%) followed by M. simiae (7/49=14%), MAC (3/49=6%), 
M. avium (2/49=4%), M. kansasii (2/49=2%), M. europaeum (2/49=4%), M. timonense 
(1/49=2%), M. yongonense (1/49=2%), M. szulgai (1/49=2%), M. parascrofulaceum 
(1/49=2%),M. scrofulaceum (1/49=2%), M.flavescens(1/49=2%) and M. 
longobardum(1/49=2%).  
NTM-Network European Trials Group (NET) network conducted a multi-centric study in 
2008 to find the relative distribution of the different NTM from pulmonary samples. 91 
different NTM species were identified using line probe assay. Mycobacterium avium 
complex (MAC) predominated in most countries (47%), followed by M. gordonae (11%). 
M. gordonae and M. xenopi had a high rate of isolation in Europe. Isolates from Asia 
(Japan, South Korea and Taiwan) were predominantly MAC (54%) followed by a 
significant proportion of rapid growers (31%)(121).In a study from north India by Umrao 
et.al, the slow growers were isolated less frequently (41%) compared to rapid growers 
(59% of isolates) (34). 
The second commonest clinical presentation of slow growers was disseminated illness. 
Slow growers such asM. avium (4/7=57%),M. intracellulare (2/7= 58.5%) and M. 
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simiae(1/7=14%) were isolated from bone marrow and lymph node specimens of 7 
patients in this study. Out of the 7 patients, 6 were diagnosed with Acquired 
Immunodeficiency Syndrome. Median CD4 count of the patients in this study was 124 
cells/cu.mm. Our findings are consistent with other studies on immunocompromised 
individuals by Varley et.al and Dhar et.al with disseminated infection in which M.avium 
is the most common species implicated (123,124).However, Varley et al found very low 
median CD4 count of 10cells / mm3 in their patients with disseminated NTM 
disease(13). 
6.4.2 Clinical presentation of rapid growers 
Most rapid growers were associated with extrapulmonary infections (post-operative 
wound infection, bacteremia, ocular infection, urinary tract infection) in our setting with 
M. abscessus (23 out of 32 cases =71.8%) being the most common. M. 
fortuitum(4/32=12.5%), M. farcinogenes (1/32= 3%), M. phocaicum (1/32= 3%), M. 
mucogenicum (1/32=3%), M. bacteremicum (1/32=3%) and M.goodii (1/32=3%) are the 
other species identified from these samples. This is in agreement with the results from 
east Asian countries and north India(34,121,125). However, in a study done in 116 
patients by Helou et.al at USA, most commonly encountered mycobacterial species was 
M. mucogenicum,(39%) (126). 
Among the 9 rapid growers (18.4%) causing pulmonary disease, 5 were M. fortuitum 
(5/49= 10%) and 4 were M. abscessus (4/49=8%). Pulmonary disease is an uncommon 
presentation of rapid growers in our setting while comparing with NTM-NET study 
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.Umrao et.alfound a high prevalence of M.abscessus (31%) followed by M.fortuitum 
(20%) in North India in patients with pulmonary disease(34). 
6.4 Risk factors of NTM 
Pulmonary NTM infections often occur in the context of preexisting lung disease, 
especially bronchiectasis, pneumoconiosis, chronic obstructive pulmonary disease 
(COPD)and cystic fibrosis. In this study, twenty-five patients (25/50= 50%)had past 
history of tuberculosis and twenty (20/50= 40%) of them had associated bronchiectasis. 
Lung damage due to previous tuberculosis is a risk factor for NTM pulmonary disease 
according to various studies (127,128). Studies done by Xu et al from China, Mirsaeidi et 
al from USA and Fowler et al from UK have analyzed the rate of NTM disease in 
patients with bronchiectasis and it was found to be variable from 5 to 30% (129–131). 
Most common extrapulmonary manifestation in this study was skin and soft tissue 
infections (16/90 =17%) and predominant type was post- operative wound infections.This 
is consistent with the rise in prevalence of SSTI due to NTM in various parts of the 
world. A study from Oregon, USA, found the incidence of SSTI to be 0.9 cases per 
100,000 patients and data from Taiwan suggests an increasing incidence of SSTI of 1.67 
to 6.7 per 100,000 population over 8 years(132,133). 
NTM bacteremia was seen in 7 patients on prolonged hospitalization of more than 2 
weeks with central venous line in-situ,who had undergone invasive procedures of the 
cardiovascular system (stent, valve repair) and therapy with immunosuppressants for 
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haematological malignancies orimmunomodulators for immune system disorders. This 
correlates with studies from other centers(134). 
6.5 Species identification of NTM 
6.5.1 MALDI-TOF  
MALDI-TOF-MS is one of the newest techniques introduced for the identification of 
NTM. The accuracy of the MALDI- TOF- MS is dependent upon obtaining good quality 
spectra which can be challenging due to the complex cell walls of mycobacteria. 
In this study, isolates were tested using the VITEK MS system (bioMérieux, France), and 
the results were analyzed using knowledge base Version 3.0, which includes 49 
Mycobacterium species [45 NTM (including 23 slow growers and 22 rapid growers) and 
4 MTBC]. Seventy five of the 90(83.3%) isolates tested were identified up to species or 
complex/group level. 13/90(14%) were not identified and 2/90(2%) were misidentified as 
non-mycobacterial species. Of the 13 species which were not identified, 4 were not in the 
database, namely M. europaeum(2 isolates), M. yongonense and M. longobardum. 
However, M. intracellulare (6/90= 6.6%), M. abscessus(2/90= 2%),and M. avium(1/90= 
1.1%) were available in the database, but were not identified. Other species which were 
misidentified- M. timonense was identified as M. intracellulare, M. parascrofulaceum 
was identified as M. scrofulaceum, M. bacteremicum was identified as M. neoaurum and 
M. farcinogenes was identified as M. fortuitum group due to the close phylogenetic 
relationship between these species. 
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In a similar study done by Luo et.al on evaluation of VITEK MS version 3.0, 
425/507(83.8%) isolates were initially identified, and 51/507(10.1%) additional isolates 
were identified on repeat, with 23/507 (4.5%) isolates remaining unidentified and 
8/507(1.6%) isolates misidentified at species level. Among slow growers, only 2/56 
(3.6%) M. avium and 3/153 (2%) M. intracellulare were unidentiﬁed, which was 
marginally better than our findings(135). 
Limitations of the MALDI-TOF-MS with NTM include lack of discrimination with some 
clinically important closely related species and subspecies including;M. chelonae and M. 
abscessus; M. intracellulare and M. chimaera; M. mucogenicum and M. phocaicum; 
subspecies of M. avium and M. abscessus; and species withinthe M. fortuitum group. If 
no identification is achieved with a good quality spectrum, this may mean that the 
organism is not represented in the database being applied.These databases are being 
developed and updated, and there is no public database to use as an additional reference 
to the commercial companies that market MALDI instrumentation. In contrast, if the 
spectral pattern is poor, there may be mixed culture present, and colony purity should be 
confirmed. 
6.5.2 16S rRNA sequencing 
Sequencing of the16S rRNA gene (approximately 1500-bp) is the most universally used 
sequencing method for identification of bacteria and also is considered a gold standard 
for identification of NTM species. Region A at the 5′ end contains most of the species-
specific or ―signature sequences‖ in mycobacteria. In this study, partial sequencing of 
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16S rRNA gene of 90 NTM isolates was performed, the details of which are discussed 
above. Three isolates which were identified as M. avium complex by 16S rRNA 
sequencing, were found to be M. intracellulare on ITS sequencing(42).  
6.5.3 Internal transcribed spacer (ITS) sequencing 
The sequence of the ITS 1 region is a 200–330-bp target region that separates the 16S and 
23S rRNA genes. Several primer sites for amplification and sequencing of this segment 
have been proposed. The ITS 1 sequence has a high variability that can be used for 
species discrimination especially with slowly growing species including MAC.  
In this study, ITS sequencing was performed on the slow growers. All the MAC isolates 
were identified upto the species level. M. avium was identified upto subspecies level. Out 
of the 6 Mycobacterium avium isolates, all were identified as M. avium subsp. 
hominisuis, which is the most pathogenic subspecies to humans according to various 
studies(81,136). Therefore, ITS sequencing can be used as an additional method over 16s 
rRNA sequencing for identification of slow growing as well as novel / rare NTM species. 
6.5.4 MALDI-TOF Vs sequencing 
Total concordanceof MALDI-TOF with the gold standard 16S rRNA sequencing was 
83.33%(95% CI:74.00- 90.4%). Concordance of MALDI-TOF for the rapid growers with 
16S rRNA sequencing was 94.5% (95% CI:81.3- 99.4) and for slow growers it was 
77.5% (95% CI: 63.9- 81.4). 
The concordance of MALDI-TOF with ITS sequencing (for slow growers) was found to 
be 76% (95% CI: 63.9- 81.4). 
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In a study done by Barbara Body et.al, 92% percent of the slowly growing NTM and 
98% of the rapidly growing mycobacteria (RGM) were correctly identiﬁed to the species, 
complex, or group level by MALDI-TOF (using VITEK MS ver 3.0) compared to 
sequencing of partial 16S rRNA genes and several additional housekeeping genes (rpoB, 
hsp65, secA,ITS, gyrB, and erm genes)(100).However, in our study the concordance 
between MALDI-TOF and sequencing for identification of slow growers was lower. 
There were no similar studies from India. 
6.5.5 Cost analysis: MALDI-TOF Vs sequencing 
MALDI-TOF is less expensive per test, after the initial purchase of the mass 
spectrometry instrument, which makes it a suitable assay for routine diagnostics. 
Sequencing is 5 to 6 times more expensive than MALDI-TOF and therefore should be 
used as a confirmatory test. 
6.5.6 Technology 
MALDI-TOF requires only protein extraction, which is a simple technique which can be 
performed by any laboratory technologist in a routine clinical microbiology laboratory 
setting. However, sequencing needs trained personnel for the procedure in a molecular 
laboratory setting. 
6.6 Turnaround time 
MALDI-TOF is a rapid method which will take only 1.5 to 2 hours for the whole 
procedure, whereas sanger sequencing will take on average 12- 24 hours of turnaround 
time(42). 
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Proposed diagnostic algorithm for routine speciation of NTMs in a diagnostic 
laboratory: 
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7. LIMITATIONS 
a) ITS sequencing of rapid growers 
ITS sequencing of rapid growers could not be done as the primers we selected amplified 
only the ITS region of slow growers. 
b) 16S rRNA sequencing 
Three isolates could not be included in this study as the Lowenstein Jensen medium was 
contaminated and the sequencing identified it as non-mycobacterial species or uncultured 
bacterium clone. 
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8. SUMMARY  
 90 Mycobacteria isolates was included in this study to evaluate the MALDI TOF 
against Molecular sequencing methods for the rapid and accurate speciation of 
Non-tuberculous mycobacteria 
o Slow growing NTM- 49 
o Rapidly growing Mycobacteria- 41 
 Most common Slow growing NTM was M.intracellulare(21%) followed by M. 
simiae (8%) 
o Most common clinical presentation was pulmonary infection (55%) 
 Most common rapidly growing NTM was M. abscessus(28.8%) followed by 
M.fortuitum (11 %) 
o The most common clinical presentation was skin and soft tissue infection 
(56%) 
 83 % (70/90) NTMs were identifies correctly upto species or complex/ group level 
using MALDI TOF 
 The concordance of various tests was as follows 
o MALDI TOF vs 16s rRNA sequencing- Slow growers 
 77.5% (95% CI: 63.9- 81.4) 
o MALDI TOF vs 16s rRNA sequencing – Rapid growers 
 94.5% (95% CI:81.3- 99.4) 
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CONCLUSION 
MALDI-TOF assay can be used as a rapid and cost-effective method for identification of 
NTM in a routine diagnostic laboratory especially for the rapidly growing NTMs. 
However, for the slow growing and novel or rare NTMs additional sequencing of 16s 
rRNA and ITS region need to be done for accurate identification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
108 
 
BIBLIOGRAPHY 
1.  Goodfellow M, Magee JG. Taxonomy of Mycobacteria. In: Mycobacteria [Internet]. 
Springer, Boston, MA; 1998 [cited 2018 Jul 18]. p. 1–71. Available from: 
https://link.springer.com/chapter/10.1007/978-1-4615-5987-0_1 
2.  Mycobacterium [Internet]. [cited 2018 Jul 17]. Available from: 
http://www.bacterio.net/mycobacterium.html 
3.  Perzigian AJ, Widmer L. Evidence for tuberculosis in a prehistoric population. JAMA. 
1979 Jun 15;241(24):2643–6.  
4.  Ancient Skeletal Evidence for Leprosy in India (2000 B.C.) [Internet]. [cited 2018 Jul 21]. 
Available from: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0005669 
5.  v31n1a09.pdf [Internet]. [cited 2018 Jul 21]. Available from: 
http://ila.ilsl.br/pdfs/v31n1a09.pdf 
6.  [The etiology of tuberculosis by Dr. Robert Koch. From the Berliner Klinische 
Wochenschrift, Volume 19 (1882)]. Zentralbl Bakteriol Mikrobiol Hyg A. 1982 
Mar;251(3):287–96.  
7.  Hoff G. Diseases of Amphibians and Reptiles. Springer Science & Business Media; 2012. 
776 p.  
8.  et Tavel A. Recherches sur le bacille de Lustgarten. Arch Physiol Norm Pathol. 1885;3:303.  
9.  Marzinowski, E. J. Ueber einige in den Krypten der Gaumenmandeln gefundene 
Bacillenarten. Zentralbl Bakteriol Parasitol 1. 1900;28:39.  
10.  Lichtenstein, E. Ueber das Vorkommen von Pseudotuberkelbacillen im menschlichen 
Sputum. Z Tuberk. 1904;11:439.  
11.  Ophiils, W. Chronic subcutaneous abscess in man containing acid-proof bacilli in pure 
culture. J Med Res. 1904;1:439.  
12.  Cobbett L. AN ACID-FAST BACILLUS OBTAINED FROM A PUSTULAR ERUPTION. 
Br Med J. 1918 Aug 17;2(3007):158–9.  
13.  Aronson, J. D. Spontaneous tuberculosis in salt water fish, J Infect Dis. J Infect Dis. 
1926;(39):315.  
14.  Landau, A S W.Jr. Dissociation of two unusual acid-fast organisms isolated from human 
sources. J Infect Dis. 1936;58:247–58.  
15.  Da Costa Cruz J. ―Myco-bacterium fortuitum,‖ an Acid-fast Organism Pathogenic for Man. 
Acta Med Rio de Janeiro. 1938;1:297–301.  
109 
 
16.  Norden A, Linell F. A new type of pathogenic Mycobacterium. Nature. 1951 Nov 
10;168(4280):826.  
17.  Feldman, W A W, Davies, R., Moses, H. E. An unusual mycobacterium isolated from 
sputum of a man suffering from pulmonary disease of long duration. Am Rev Tuberc. 
1943;(48):82.  
18.  Feldman, W. H K AG. Mycobacteria of human origin resembling Mycobacterium avium. 
Proc 15th International Veterinary Congress, Stockholm. 1953;1:159.  
19.  Moore M, Frerichs JB. An Unusual Acid-Fast Infection of the Knee with Subcutaneous, 
Abscess-Like Lesions of the Gluteal Region: Report of a Case with a Study of the 
Organism, Mycobacterium abscessus, n. sp.1. Journal of Investigative Dermatology. 1953 
Feb 1;20(2):133–69.  
20.  Gibson JB. Infection of the lungs by ―saprophytic‖ mycobacteria in achalasia of the cardia, 
with report of a fatal case showing lipoid pneumonia due to milk. The Journal of Pathology 
and Bacteriology. 1953 Jan 1;65(1):239–51.  
21.  Buhler VB, Pollak A. Human infection with atypical acid-fast organisms; report of two 
cases with pathologic findings. Am J Clin Pathol. 1953 Apr;23(4):363–74.  
22.  Palmer CE, Krohn EF, Manos NE, Edwards LB. Tuberculin sensitivity of young adults in 
the United States. Public Health Rep. 1956 Jul;71(7):633–45.  
23.  Timpe A, Runyon EH. The relationship of ―Atypical‖ acid-fast bacteria to human disease: 
A preliminary report. The Journal of Laboratory and Clinical Medicine. 1954 Aug 
1;44(2):202–9.  
24.  Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis. 
1979 Jan;119(1):107–59.  
25.  Wolinsky E. Mycobacterial lymphadenitis in children: a prospective study of 105 
nontuberculous cases with long-term follow-up. Clin Infect Dis. 1995 Apr;20(4):954–63.  
26.  Falkinham JO. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol 
Rev. 1996 Apr;9(2):177–215.  
27.  Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, et al. 
Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an 
emerging public health disease. Am J Respir Crit Care Med. 2010 Oct 1;182(7):977–82.  
28.  Marras TK, Mendelson D, Marchand-Austin A, May K, Jamieson FB. Pulmonary 
Nontuberculous Mycobacterial Disease, Ontario, Canada, 1998–2010. Emerg Infect Dis. 
2013 Nov;19(11):1889–91.  
29.  Marras TK, Daley CL. Epidemiology of human pulmonary infection with mycobacteria 
nontuberculous. Clinics in Chest Medicine. 2002 Sep 1;23(3):553–67.  
110 
 
30.  Brode SK, Daley CL, Marras TK. The epidemiologic relationship between tuberculosis and 
non-tuberculous mycobacterial disease: a systematic review. Int J Tuberc Lung Dis. 2014 
Nov;18(11):1370–7.  
31.  Jani MN, Rodrigues CS, Mehta AP. The Neglected and Often Ignored: Nontuberculous 
Mycobacteria. J Glob Infect Dis. 2011;3(1):94.  
32.  Sharma P, Singh D, Sharma K, Verma S, Mahajan S, Kanga A. Are We Neglecting 
Nontuberculous Mycobacteria Just as Laboratory Contaminants? Time to Reevaluate 
Things [Internet]. Journal of Pathogens. 2018 [cited 2018 Aug 30]. Available from: 
https://www.hindawi.com/journals/jpath/2018/8907629/ 
33.  Jesudason MV, Gladstone P. Non tuberculous mycobacteria isolated from clinical 
specimens at a tertiary care hospital in South India. Indian Journal of Medical 
Microbiology. 2005 Jul 1;23(3):172.  
34.  Umrao J, Singh D, Zia A, Saxena S, Sarsaiya S, Singh S, et al. Prevalence and species 
spectrum of both pulmonary and extrapulmonary nontuberculous mycobacteria isolates at a 
tertiary care center. International Journal of Mycobacteriology. 2016 Sep 1;5(3):288–93.  
35.  Haworth CS, Floto RA. Introducing the new BTS Guideline: Management of non-
tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(11):969–70.  
36.  Cavalier-Smith T. The phagotrophic origin of eukaryotes and phylogenetic classification of 
Protozoa. Int J Syst Evol Microbiol. 2002 Mar;52(Pt 2):297–354.  
37.  Magee JG, Ward AC. Mycobacterium. In: Bergey‘s Manual of Systematics of Archaea and 
Bacteria [Internet]. American Cancer Society; 2015 [cited 2018 Jul 18]. p. 1–84. Available 
from: https://onlinelibrary.wiley.com/doi/abs/10.1002/9781118960608.gbm00029 
38.  STACKEBRANDT E, RAINEY FA, WARD-RAINEY NL. Proposal for a New Hierarchic 
Classification System, Actinobacteria classis nov. International Journal of Systematic and 
Evolutionary Microbiology. 1997;47(2):479–91.  
39.  Chester FD. Report of the mycologist: Bacteriological work. Delaware Agric Exp Station 
Bull. 1897;(9):38–145.  
40.  Lehmann KB, Neumann RO. Atlas und Grundriss der Bakteriologie und Lehrbuch der 
speziellen bakteriologischen Diagnostik. München: J.F. Lehmann; 1896.  
41.  Goodfellow M, Jones AL. Corynebacteriales ord. nov. In: Bergey‘s Manual of Systematics 
of Archaea and Bacteria [Internet]. American Cancer Society; 2015 [cited 2018 Sep 6]. p. 
1–14. Available from: 
https://onlinelibrary.wiley.com/doi/abs/10.1002/9781118960608.obm00009 
42.  Pfyffer GE. Mycobacterium: General Characteristics, Laboratory Detection, and Staining 
Procedures*. Manual of Clinical Microbiology, Eleventh Edition. 2015 Jun 1;536–69.  
111 
 
43.  Ludwig W, Euzéby J, Schumann (auth.) P, Goodfellow M, Kämpfer P, Busse H-J, et al. 
Bergey‘s Manual® of Systematic Bacteriology: Volume Five The Actinobacteria, Part A 
and B [Internet]. 2nd ed. Springer-Verlag New York; 2012 [cited 2018 Jul 21]. Available 
from: http://gen.lib.rus.ec/book/index.php?md5=2b33da381bcaddba93ecf3369f144911 
44.  Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An 
Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous 
Mycobacterial Diseases. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367–416.  
45.  Runyon EH. Anonymous Mycobacteria in Pulmonary Disease. Medical Clinics of North 
America. 1959 Jan 1;43(1):273–90.  
46.  Chapman J. The Atypical Mycobacteria and Human Mycobacteriosis [Internet]. Springer 
US; 1977 [cited 2018 Sep 7]. (Current Topics in Infectious Disease). Available from: 
//www.springer.com/gp/book/9781468423129 
47.  Woods GL, Washington JA. Mycobacteria other than Mycobacterium tuberculosis: review 
of microbiologic and clinical aspects. Rev Infect Dis. 1987 Apr;9(2):275–94.  
48.  Brennan PJ, Goren MB. Structural studies on the type-specific antigens and lipids of the 
mycobacterium avium. Mycobacterium intracellulare. Mycobacterium scrofulaceum 
serocomplex. Mycobacterium intracellulare serotype 9. J Biol Chem. 1979 May 
25;254(10):4205–11.  
49.  Daffé M, Draper P. The envelope layers of mycobacteria with reference to their 
pathogenicity. Adv Microb Physiol. 1998;39:131–203.  
50.  Zuber B, Chami M, Houssin C, Dubochet J, Griffiths G, Daffé M. Direct Visualization of 
the Outer Membrane of Mycobacteria and Corynebacteria in Their Native State. J Bacteriol. 
2008 Aug;190(16):5672–80.  
51.  Marrakchi H, Lanéelle M-A, Daffé M. Mycolic Acids: Structures, Biosynthesis, and 
Beyond. Chemistry & Biology. 2014 Jan 16;21(1):67–85.  
52.  Minnikin DE. Chemical principles in the organization of lipid components in the 
mycobacterial cell envelope. Research in Microbiology. 1991 Jan 1;142(4):423–7.  
53.  Alderwick LJ, Harrison J, Lloyd GS, Birch HL. The Mycobacterial Cell Wall—
Peptidoglycan and Arabinogalactan. Cold Spring Harb Perspect Med [Internet]. 2015 Aug 
[cited 2018 Sep 8];5(8). Available from: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526729/ 
54.  Roux A-L, Viljoen A, Bah A, Simeone R, Bernut A, Laencina L, et al. The distinct fate of 
smooth and rough Mycobacterium abscessus variants inside macrophages. Open Biol 
[Internet]. 2016 Nov 30 [cited 2018 Sep 20];6(11). Available from: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133439/ 
112 
 
55.  Gutiérrez AV, Viljoen A, Ghigo E, Herrmann J-L, Kremer L. Glycopeptidolipids, a 
Double-Edged Sword of the Mycobacterium abscessus Complex. Front Microbiol. 
2018;9:1145.  
56.  Honda JR, Bai X, Chan ED. Elucidating the Pathogenesis of Nontuberculous Mycobacterial 
Lung Disease: Lesson from the Six Blind Men and the Elephant. Am J Respir Cell Mol 
Biol. 2018;58(2):142–3.  
57.  Manual of Clinical Microbiology, Eleventh Edition [Internet]. American Society of 
Microbiology; 2015 [cited 2018 Sep 6]. Available from: 
http://www.asmscience.org/content/book/10.1128/9781555817381 
58.  Falkinham JO. Environmental sources of nontuberculous mycobacteria. Clin Chest Med. 
2015 Mar;36(1):35–41.  
59.  Taylor RH, Falkinham JO, Norton CD, LeChevallier MW. Chlorine, chloramine, chlorine 
dioxide, and ozone susceptibility of Mycobacterium avium. Appl Environ Microbiol. 2000 
Apr;66(4):1702–5.  
60.  Parker BC, Ford MA, Gruft H, Falkinham JO. Epidemiology of infection by 
nontuberculous mycobacteria. IV. Preferential aerosolization of Mycobacterium 
intracellulare from natural waters. Am Rev Respir Dis. 1983 Oct;128(4):652–6.  
61.  Primm TP, Falkinham JO. Nontuberculous Mycobacteria. In: International Encyclopedia of 
Public Health [Internet]. Elsevier; 2017 [cited 2018 Aug 6]. p. 257–63. Available from: 
http://linkinghub.elsevier.com/retrieve/pii/B9780128036785001351 
62.  Goslee S, Wolinsky E. Water as a source of potentially pathogenic mycobacteria. Am Rev 
Respir Dis. 1976 Mar;113(3):287–92.  
63.  von Reyn CF, Maslow JN, Barber TW, Falkinham JO, Arbeit RD. Persistent colonisation of 
potable water as a source of Mycobacterium avium infection in AIDS. Lancet. 1994 May 
7;343(8906):1137–41.  
64.  Opportunistic pathogens enriched in showerhead biofilms [Internet]. [cited 2018 Sep 8]. 
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2752528/ 
65.  Tu H-Z, Chen C-S, Huang T-S, Huang W-K, Chen Y, Liu Y, et al. Use of a Disposable 
Water Filter for Prevention of False-Positive Results due to Nontuberculosis Mycobacteria 
in a Clinical Laboratory Performing Routine Acid-Fast Staining for Tuberculosis. Appl 
Environ Microbiol. 2007 Oct;73(19):6296–8.  
66.  NTM Causes [Internet]. National Jewish Health. [cited 2018 Sep 8]. Available from: 
https://nationaljewish.org/conditions/ntm-nontuberculous-mycobacteria/NTM-
Nontuberculous-Mycobacteria-Overview/causes 
67.  Alcaide F, Esteban J. [Cutaneous and soft skin infections due to non-tuberculous 
mycobacteria]. Enferm Infecc Microbiol Clin. 2010 Jan;28 Suppl 1:46–50.  
113 
 
68.  Guglielmetti L, Mougari F, Lopes A, Raskine L, Cambau E. Human infections due to 
nontuberculous mycobacteria: the infectious diseases and clinical microbiology specialists‘ 
point of view. Future Microbiology. 2015 Sep 1;10(9):1467–83.  
69.  Nishiuchi Y, Iwamoto T, Maruyama F. Infection Sources of a Common Non-tuberculous 
Mycobacterial Pathogen, Mycobacterium avium Complex. Front Med (Lausanne) 
[Internet]. 2017 Mar 7 [cited 2018 Sep 8];4. Available from: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339636/ 
70.  Huitt GA, Daley CL. Nontuberculous Mycobacteria. Clinics in Chest Medicine. 2015 Mar 
1;36(1):i.  
71.  Thomson RM, Armstrong JG, Looke DF. Gastroesophageal Reflux Disease, Acid 
Suppression, and Mycobacterium avium Complex Pulmonary Disease. Chest. 2007 Apr 
1;131(4):1166–72.  
72.  Chan ED, Iseman MD. Slender, Older Women Appear to Be More Susceptible to 
Nontuberculous Mycobacterial Lung Disease. Gender Medicine. 2010 Feb 1;7(1):5–18.  
73.  Dhillon SS, Watanakunakorn C. Lady Windermere Syndrome: Middle Lobe Bronchiectasis 
and Mycobacterium avium Complex Infection Due to Voluntary Cough Suppression. Clin 
Infect Dis. 2000 Mar 1;30(3):572–5.  
74.  Katila ML, Brander E, Backman A. Neonatal bcg vaccination and mycobacterial cervical 
adenitis in childhood. Tubercle. 1987 Dec 1;68(4):291–6.  
75.  Wagner D, Young LS. Nontuberculous Mycobacterial Infections: A Clinical Review. 
Infection. 2004 Oct 1;32(5):257–70.  
76.  Iseman MD, Buschman DL, Ackerson LM. Pectus excavatum and scoliosis. Thoracic 
anomalies associated with pulmonary disease caused by Mycobacterium avium complex. 
Am Rev Respir Dis. 1991 Oct;144(4):914–6.  
77.  Kim RD, Greenberg DE, Ehrmantraut ME, Guide SV, Ding L, Shea Y, et al. Pulmonary 
nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. 
Am J Respir Crit Care Med. 2008 Nov 15;178(10):1066–74.  
78.  Sood A, Sreedhar R, Kulkarni P, Nawoor AR. Hypersensitivity Pneumonitis-like 
Granulomatous Lung Disease with Nontuberculous Mycobacteria from Exposure to Hot 
Water Aerosols. Environ Health Perspect. 2007 Feb;115(2):262–6.  
79.  Eikani MS, Nugent M, Poursina A, Simpson P, Levy H. Clinical course and significance of 
nontuberculous mycobacteria and its subtypes in cystic fibrosis. BMC Infect Dis. 2018 Jul 
6;18(1):311.  
80.  Tortoli E. Clinical manifestations of nontuberculous mycobacteria infections. Clinical 
Microbiology and Infection. 2009 Oct 1;15(10):906–10.  
114 
 
81.  Van Ingen J. 32 - Nontuberculous Mycobacterial Diseases. In: Cohen J, Powderly WG, 
Opal SM, editors. Infectious Diseases (Fourth Edition) [Internet]. Elsevier; 2017 [cited 
2018 Jul 17]. p. 285-291.e1. Available from: 
http://www.sciencedirect.com/science/article/pii/B9780702062858000320 
82.  MAC Adult and Adolescent Opportunistic Infection [Internet]. AIDSinfo. [cited 2018 Sep 
24]. Available from: https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-
opportunistic-infection/326/mac 
83.  Pechère M, Opravil M, Wald A, Chave J-P, Bessesen M, Sievers A, et al. Clinical and 
Epidemiologic Features of Infection With Mycobacterium genavense. Arch Intern Med. 
1995 Feb 27;155(4):400–4.  
84.  Schaeffer F, Kennedy B, Landes N, Trevino E, Vance P, Weissfeld AS. Mycobacterium 
chimaera: Coming out of Nowhere to Dominate 2016 Infection Prevention Discussions. 
Clinical Microbiology Newsletter. 2017 Mar 15;39(6):43–7.  
85.  Woodring JH, Vandiviere HM. Pulmonary disease caused by nontuberculous mycobacteria. 
J Thorac Imaging. 1990 Apr;5(2):64–76.  
86.  Christensen EE, Dietz GW, Ahn CH, Chapman JS, Murry RC, Anderson J, et al. Initial 
roentgenographic manifestations of pulmonary Mycobacterium tuberculosis, M kansasii, 
and M intracellularis infections. Chest. 1981 Aug;80(2):132–6.  
87.  Levin DL. Radiology of pulmonary Mycobacterium avium-intracellulare complex. Clin 
Chest Med. 2002 Sep;23(3):603–12.  
88.  Maurya. Recent methods for diagnosis of nontuberculous mycobacteria infections: 
Relevance in clinical practice [Internet]. [cited 2018 Sep 9]. Available from: 
http://www.bmbtrj.org/article.asp?issn=2588-
9834;year=2017;volume=1;issue=1;spage=14;epage=18;aulast=Maurya 
89.  WHO | Fluorescent light-emitting diode (LED) microscopy for diagnosis of tuberculosis 
policy [Internet]. WHO. [cited 2018 Oct 3]. Available from: 
http://www.who.int/tb/publications/2011/led_microscopy_diagnosis_9789241501613/en/ 
90.  Procop GW, Koneman EW. Koneman‘s Color Atlas and Textbook of Diagnostic 
Microbiology. Lippincott Williams & Wilkins; 2016. 1936 p.  
91.  Shenoy VP, Mukhopadhyay C. Rapid Immunochromatographic Test for the Identification 
and Discrimination of Mycobacterium tuberculosis Complex Isolates from Non-tuberculous 
Mycobacteria. J Clin Diagn Res. 2014 Apr;8(4):DC13-15.  
92.  Kumar VG, Urs TA, Ranganath RR. MPT 64 Antigen detection for Rapid confirmation of 
M.tuberculosis isolates. BMC Res Notes. 2011 Mar 24;4:79.  
93.  van Ingen J. Microbiological Diagnosis of Nontuberculous Mycobacterial Pulmonary 
Disease. Clinics in Chest Medicine. 2015 Mar 1;36(1):43–54.  
115 
 
94.  Somoskovi A, Salfinger M. Nontuberculous mycobacteria in respiratory infections: 
advances in diagnosis and identification. Clin Lab Med. 2014 Jun;34(2):271–95.  
95.  Russo C, Tortoli E, Menichella D. Evaluation of the New GenoType Mycobacterium Assay 
for Identification of Mycobacterial Species. Journal of Clinical Microbiology. 2006 Feb 
1;44(2):334–9.  
96.  Tortoli E, Mariottini A, Mazzarelli G. Evaluation of INNO-LiPA MYCOBACTERIA v2: 
Improved Reverse Hybridization Multiple DNA Probe Assay for Mycobacterial 
Identification. J Clin Microbiol. 2003 Sep;41(9):4418–20.  
97.  Neuschlova M, Vladarova M, Kompanikova J, Sadlonova V, Novakova E. Identification of 
Mycobacterium Species by MALDI-TOF Mass Spectrometry. Adv Exp Med Biol. 
2017;1021:37–42.  
98.  Mediavilla-Gradolph MC, De Toro-Peinado I, Bermúdez-Ruiz MP, García-Martínez M de 
los Á, Ortega-Torres M, Montiel Quezel-Guerraz N, et al. Use of MALDI-TOF MS for 
Identification of Nontuberculous Mycobacterium Species Isolated from Clinical Specimens 
[Internet]. BioMed Research International. 2015 [cited 2018 Feb 13]. Available from: 
https://www.hindawi.com/journals/bmri/2015/854078/ 
99.  Saleeb PG, Drake SK, Murray PR, Zelazny AM. Identification of Mycobacteria in Solid-
Culture Media by Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass 
Spectrometry▿ . J Clin Microbiol. 2011 May;49(5):1790–4.  
100.  Body BA, Beard MA, Slechta ES, Hanson KE, Barker AP, Babady NE, et al. Evaluation of 
the Vitek MS v3.0 Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass 
Spectrometry System for Identification of Mycobacterium and Nocardia Species. J Clin 
Microbiol. 2018 Jun;56(6).  
101.  Brown-Elliott BA, Wallace RJ. Enhancement of Conventional Phenotypic Methods with 
Molecular-Based Methods for the More Definitive Identification of Nontuberculous 
Mycobacteria. Clinical Microbiology Newsletter. 2012 Jul 15;34(14):109–15.  
102.  Brown-Elliott BA, Philley JV. Rapidly Growing Mycobacteria. Microbiology Spectrum 
[Internet]. 2017 Jan 13 [cited 2018 Sep 9];5(1). Available from: 
http://www.asmscience.org/content/journal/microbiolspec/10.1128/microbiolspec.TNMI7-
0027-2016 
103.  Yu X, Lu L, Chen G, Liu Z-G, Lei H, Song Y, et al. Identification and Characterization of 
Non-Tuberculous Mycobacteria Isolated from Tuberculosis Suspects in Southern-Central 
China. PLOS ONE. 2014 Dec 2;9(12):e114353.  
104.  Roth A, Fischer M, Hamid ME, Michalke S, Ludwig W, Mauch H. Differentiation of 
Phylogenetically Related Slowly Growing Mycobacteria Based on 16S-23S rRNA Gene 
Internal Transcribed Spacer Sequences. J Clin Microbiol. 1998 Jan 1;36(1):139–47.  
116 
 
105.  Telenti A, Marchesi F, Balz M, Bally F, Böttger EC, Bodmer T. Rapid identification of 
mycobacteria to the species level by polymerase chain reaction and restriction enzyme 
analysis. J Clin Microbiol. 1993 Feb;31(2):175–8.  
106.  Adekambi T. rpoB gene sequence-based characterization of emerging non-tuberculous 
mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium 
phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. INTERNATIONAL 
JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY. 2006 Jan 
1;56(1):133–43.  
107.  Zwaan R de, Ingen J van, Soolingen D van. Utility of rpoB Gene Sequencing for 
Identification of Nontuberculous Mycobacteria in the Netherlands. J Clin Microbiol. 2014 
Jul 1;52(7):2544–51.  
108.  Adékambi T, Colson P, Drancourt M. rpoB-based identification of nonpigmented and late-
pigmenting rapidly growing mycobacteria. J Clin Microbiol. 2003 Dec;41(12):5699–708.  
109.  Tortoli E, Simonetti MT, Lavinia F. Evaluation of reformulated chemiluminescent DNA 
probe (AccuProbe) for culture identification of Mycobacterium kansasii. J Clin Microbiol. 
1996 Nov;34(11):2838–40.  
110.  Richter E, Niemann S, Rüsch-Gerdes S, Hoffner S. Identification of Mycobacterium 
kansasii by using a DNA probe (AccuProbe) and molecular techniques. J Clin Microbiol. 
1999 Apr;37(4):964–70.  
111.  Brown-Elliott BA, Nash KA, Wallace RJ. Antimicrobial susceptibility testing, drug 
resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin 
Microbiol Rev. 2012 Jul;25(3):545–82.  
112.  M24A2E | Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic 
Actinomycetes, 2nd Edition [Internet]. Clinical & Laboratory Standards Institute. [cited 
2018 Sep 24]. Available from: 
https://clsi.org/standards/products/microbiology/documents/m24/ 
113.  Lindeboom JA, Kuijper EJ, Bruijnesteijn van Coppenraet ES, Lindeboom R, Prins JM. 
Surgical excision versus antibiotic treatment for nontuberculous mycobacterial 
cervicofacial lymphadenitis in children: a multicenter, randomized, controlled trial. Clin 
Infect Dis. 2007 Apr 15;44(8):1057–64.  
114.  Lindeboom JA. Conservative Wait-and-See Therapy Versus Antibiotic Treatment for 
Nontuberculous Mycobacterial Cervicofacial Lymphadenitis in Children. Clinical 
Infectious Diseases. 2011;52(2):180–4.  
115.  Misch EA, Saddler C, Davis JM. Skin and Soft Tissue Infections Due to Nontuberculous 
Mycobacteria. Curr Infect Dis Rep. 2018 Mar 19;20(4):6.  
117 
 
116.  Turner S, Pryer KM, Miao VP, Palmer JD. Investigating deep phylogenetic relationships 
among cyanobacteria and plastids by small subunit rRNA sequence analysis. J Eukaryot 
Microbiol. 1999 Aug;46(4):327–38.  
117.  Yu X, Lu L, Chen G, Liu Z-G, Lei H, Song Y, et al. Identification and Characterization of 
Non-Tuberculous Mycobacteria Isolated from Tuberculosis Suspects in Southern-Central 
China. PLOS ONE. 2014 Dec 2;9(12):e114353.  
118.  Mycobacterium [Internet]. [cited 2018 Sep 6]. Available from: 
http://www.bacterio.net/mycobacterium.html 
119.  Prevots DR, Marras TK. Epidemiology of Human Pulmonary Infection with 
Nontuberculous Mycobacteria: A Review. Clinics in Chest Medicine. 2015 Mar 
1;36(1):13–34.  
120.  Al EH et. Surveillance of Extrapulmonary Nontuberculous Mycobacteria Infections, 
Oregon, USA, 2007–2012 - Volume 23, Number 10—October 2017 - Emerging Infectious 
Diseases journal - CDC. [cited 2018 Oct 15]; Available from: 
https://wwwnc.cdc.gov/eid/article/23/10/17-0845_article 
121.  Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, et al. The 
geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an 
NTM-NET collaborative study. Eur Respir J. 2013 Dec;42(6):1604–13.  
122.  Shih DC. Extrapulmonary Nontuberculous Mycobacterial Disease Surveillance — Oregon, 
2014–2016. MMWR Morb Mortal Wkly Rep [Internet]. 2018 [cited 2018 Oct 15];67. 
Available from: https://www.cdc.gov/mmwr/volumes/67/wr/mm6731a3.htm 
123.  Varley CD, Ku JH, Henkle E, Schafer SD, Winthrop KL. Disseminated Nontuberculous 
Mycobacteria in HIV-Infected Patients, Oregon, USA, 2007-2012. Emerging Infect Dis. 
2017;23(3):533–5.  
124.  Dhar K, Shenoy VP, Vishwanath S, Prabhu M. Disseminated Mycobacterium avium 
intracellulare complex (MAC) disease in a retropositive patient caused by noncompliance 
of HAART. Annals of Tropical Medicine and Public Health. 2016 May 1;9(3):194.  
125.  Kham-ngam I, Chetchotisakd P, Ananta P, Chaimanee P, Sadee P, Reechaipichitkul W, et 
al. Epidemiology of and risk factors for extrapulmonary nontuberculous mycobacterial 
infections in Northeast Thailand. PeerJ. 2018 Aug 16;6:e5479.  
126.  El Helou G, Viola GM, Hachem R, Han XY, Raad II. Rapidly growing mycobacterial 
bloodstream infections. Lancet Infect Dis. 2013 Feb;13(2):166–74.  
127.  Brode SK, Daley CL, Marras TK. The epidemiologic relationship between tuberculosis and 
non-tuberculous mycobacterial disease: a systematic review. Int J Tuberc Lung Dis. 2014 
Nov;18(11):1370–7.  
118 
 
128.  Liao T-L, Lin C-F, Chen Y-M, Liu H-J, Chen D-Y. Risk Factors and Outcomes of 
Nontuberculous Mycobacterial Disease among Rheumatoid Arthritis Patients: A Case-
Control study in a TB Endemic Area. Scientific Reports. 2016 Jul 11;6:29443.  
129.  Xu J-F, Xiao H. Prevalence and Clinical Analysis of Bronchiectasis With NTM Lung 
Disease in China. CHEST. 2014 Mar 1;145(3):429A.  
130.  Mirsaeidi M, Hadid W, Ericsoussi B, Rodgers D, Sadikot RT. Non-tuberculous 
mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. 
International Journal of Infectious Diseases. 2013 Nov;17(11):e1000–4.  
131.  Fowler SJ, French J, Screaton NJ, Foweraker J, Condliffe A, Haworth CS, et al. 
Nontuberculous mycobacteria in bronchiectasis: Prevalence and patient characteristics. Eur 
Respir J. 2006 Dec;28(6):1204–10.  
132.  Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL. Nontuberculous 
Mycobacterial Disease Prevalence and Risk Factors: A Changing Epidemiology. Clin Infect 
Dis. 2009 Dec 15;49(12):e124–9.  
133.  DING LW, LAI CC, LEE LN, HSUEH PR. Disease caused by non-tuberculous 
mycobacteria in a university hospital in Taiwan, 1997–2003. Epidemiol Infect. 2006 
Oct;134(5):1060–7.  
134.  Hawkins C, Qi C, Warren J, Stosor V. Catheter-related bloodstream infections caused by 
rapidly growing nontuberculous mycobacteria: a case series including rare species. Diagn 
Microbiol Infect Dis. 2008 Jun;61(2):187–91.  
135.  Luo L, Cao W, Chen W, Zhang R, Jing L, Chen H, et al. Evaluation of the VITEK MS 
knowledge base version 3.0 for the identification of clinically relevant Mycobacterium 
species. Emerg Microbes Infect. 2018 Jul 4;7(1):114.  
136.  Tran QT, Han XY. Subspecies Identification and Significance of 257 Clinical Strains of 
Mycobacterium avium. Journal of Clinical Microbiology. 2014 Apr 1;52(4):1201–6.  
 
 
 
 
 
 
OFFICE OF RESEARCH
INSTTTUTTONAL REVTEW BOARD (rRB)
CHRISTIAI\ MEDICAL COLLEGE, VELLORE, INDIA
Dr. B.J. Prashantham, M.A., M.A., Dr. Min (ctinical)
Director, Christian Counseling Center,
Chairperson, Ethics Committee,
Dr. Anna Benjamin Pulimood, M.B.B.s., MD., ph.D.,
Chairperson, Research Committee & Principal
Dr. Biju George, M.B.B.s., MD., DM.,
Deputy Chairperson,
Secretary, Ethics Committee, IRB
Additional Vice-Principal (Research)
$$
i :i:a 
-"r,,ir'Agre efit.;'il
....'.a::a: :a;allt"
May 14,2018
Dr. Ann Susan Sam,
PG registrar,
Department of Microbiology,
Christian Medical College,
Vellore 
- 
632 002.
Sub: Fluid Research Grant: New Proposal:
Sequencing and MALDI-TOF- tools for accurate ideruification of Non-tuberculous
Mycobacteria-a Pilot study.
Dr. Ann Susan Sam , Employment Number: 21309, PG Registrar, Clinical
Microbiology, Dr. Joy Sarojini Michael, Emp. No : 50199 Microbiology. Ms. R Ranjani,
Microbiology, Dr.Marilyn Ninan, Microbiology, Dr,Naveen Kumar, Microbiology.
::-.::.., ) 
:t.!ri.Ref: IRB Min. No. | | ZZ4 iOtnCNOl dated 05.03.20 t8
Dear Dr. Ann Susan Sam, '..-.n
I enclose the followins documenti:l' r 
''r'.'::i":.:
l. lnstitutional Review gourd aiiproval
I'
Could you please sign the ug.eere;t'aild send,it l$ft Hiii.C"o.ge, Addl. Vice Principal(Research), so that the grant money can be released.,
2.
with
fi
F,\"
best wishes.
'' 
-,\-/t 
" 
Ivl
r. Biju George
Secretary (Ethics Committee)
Institutional Review Board
1-:,1i-{J (: Ic'a#E
- 
- " 
i.:,1 i;s_ ;i...?* Fi'],,,,,,rreer
SE,CF;TAt'r'-lir'r.il; ** eoutJ,. 
632 002.
. 
" 
l;;.;;;;; ;"rlege' Verr
Cc: Dr. Joy Sarojini Michael, Dept. of Microbiology, CMC, Vellore l of 4
Ethics Committee Blue, Office of Research,
Tel: 04 I 6 
- 
2284294, 2284202
lst Floor, Carman Block, Christian Medical College, Vellore, Tamil Nadu 632 002
Fax: 0416 
- 
2262788, 2284481 E-mai[: research@cmcvellore.ac.in
OFFICE OF RESEARCH
INSTITUTIONAL REVIEW BOARD (IRB)
CHRISTIAN MEDICAL COLLEGE, VELLORE, INDIA
Dr. B.J. Prashantham, M.A., M.A., Dr. Min (Clinical)
Director, Christian Counseling Center,
Chairperson, Ethics Committee.
Dr. Anna Benjamin Pulimood, M.B.B.s., MD., ph.D.,
Chairperson, Research Committee & Principal
Dr. Biju George, M.B.B.s., MD., DM.,
Deputy Chairperson,
Secretary, Ethics Committee, IRB
Additional Vice-Principal (Research)
May 14,2018
Dr. Ann Susan Sam,
PG registrar,
Department of Microbiology,
Christian Medical Collese.
Vef lore 
- 
632 002.
Sub: Fluid Research Grant: New Proposal:
Sequencing and MALDI-TOF- tools for accurate identification of Non-tuberculous
Mycobacteria-a Pilot study.
Dr. Ann Susan Sam , Employment Numberl2,l309, PG Registrar, Clinical
Microbiology, Dr. Joy Sarojini Michael, Emp. No : 50199 Microbiology, Ms. R Raniani,
Microbiology, Dr. Marilyn Ninan, Microbiology. Dr. Naveen Kumar, Microbiology.
Ref: IRB Min. No. I 1224 IDIAGNO] dated 05.03.2018
Dear Dr. Ann Susan Sam,
The Institutional Review,Board'(Blue, Research and Ethics Commi,ttee) of the Christian Medical
College, Vellore, review.ed"and discussed your project titled "Sequ-ncing and MALDI-TOF- 
,
tools for accurate identi ion of Non-tuberc.ulous Myccib'bcteria-a Pilot study" on March 05th
2018, ',:, . , ..: :,.,:,:'.:,1..: :"t,;:.i... .,: ;, , 
.
,,.,.',, $,i\ ::rrr'1 ::i-:::::\. .j,n.
Th e C om m ittil$$e\f ewed the fo l'['ow i n g doeir de n t s :
l. IRB Applicatioh format
2. Signature Page
3. Cvs of Drs. Ann, Merlin N, Naveen Kumar, Joy
4. No. of documents l - 3.
The following Institutional Review Board (Blue, Research & Ethics Committee) members were
presentatthemeetingheldonMarch05th20lSintheJacobChandyHall,Paul 6rand Building,
Christian Medical Collese. Vellore 632 004.
2of4
Ethics Committee Blue, Oflice of Research, lst Floor, Carman Block, Christian Medical College, Vellore, Tamil Nadu 632 002
Tel:0416 
-2284294,2284202 Fax: 0416 -2262788,2284481 E-mail: research@cmcvellore.ac.in
OFFICE OF RESEARCH
INSTITUTIONAL REVIEW BOARD (IRB)
CHRISTIAN MEDICAL COLLEGE, VELLORE, INDIA
Dr. B.J. Prashantham, M.A., M.A., Dr. Min (Clinical)
Director, Christian Counseling Center,
Chairperson, Ethics Committee.
Dr. Anna Benjamin Pulimood, M.B.B.s., MD., ph.D.,
Chairperson, Research Committee & Principal
Dr. Biju George, M.B.B.S., MD., DM.,
Deputy Chairperson,
Secretary, Ethics Committee, IRB
Additional Vice-Principal (Research)
Name Qualification Designation Affiliation
Dr. Biju George MBBS. MD. DM Professor, Haematology
Research), Additional
Vice Principal , Deputy
Chairperson (Research
Committee), Member
Secretary (Ethics
Committee), lRB, CMC
Vellore
Internal,
Clinician
Dr. Mathew Joseph MBBS, MCH Professor, Neurosurgery,
CMC, Vellore
Internal,
Clinician
Dr. B. J. Prashantham MA(Counseling
Psychology),
MA(Theology),
Dr. Min(Clinical
Counselline)
Chaj.-1 19on, Ethics
Comnil.lttee, IRB.
Director, Cihristian
Counseling Centre,
Vellore
External,
Social Scientist
Dr. Sowmya
Sathyendra
MBBS: MD (Gen.
Medicine) i:i ,
Professor, Medicine I I I,
CMC. Vellore
Internal,
Clinician
Dr. Thomas V Paul IVtrBBS,-MD,.DNB,
PhD .'
P ro fes so r;E n d oerino I o gy,
CMC, Vellore.:.'
Internal,
Clinician
Mr. C. Sampath BSa;,BL
t', i
..... ti
Advocate. Vellore F.xternal,
Legal Expert
Dr. Jayaprakash
Muliyil
BS€;\4BBS, MD.
MPH, Dr PH (Epid),
DMHC',,,-==
Retired P,ro.fe r, CMC,
Vellope.;" 
="'
External,
Scientist
&Eoidemiolosist
Ms. Grace Rebekha Leqturer, B i ostat i stics,
CMC. Vellore
Internal,
Statistician
Dr Sneha Varkki MBBS. DCH. DNB Professor, Paed iatrics,
CMC. Vellore
Internal,
Clinician
Dr. Shyam Kumar NK MBBS, DMRD, DNB,
FRCR. FRANZCR
Professor, Radiology,
CMC, Vellore
Internal,
Clinician
Mrs. Pattabiraman BSc, DSSA Social Worker. Vellore E,xternal,
[-ay Person
Mrs. Nirmala Marsaret MSc Nursing Professor, Medical
SurgicalNursing, CMC,
Vellore
Internal. Nurse
IRB Min. No. I 1224 IDIAGNO] dated 05.03.2018 3 of4
Ethics Committee Blue, Offrce of Research, lst Floor, Carman Block, Christian Medical College, Vellore, Tamil Nadu 632 002
Tel: Ml6 
-2284294,2284202 Fax:0416 -2262788,2284481 E-mail:research@cmcvellore.ac.in
OFFICE OF RESEARCH
INSTTTUTTONAL REVTEW BOARD (rRB)
CHRISTIAN MEDICAL COLLEGE, VELLORE, INDIA
Dr. B.J. Prashantham, M.A., M.A., Dr. Min (clinical)
Director, Christian Counseling Center,
Chairperson, Ethics Committee.
Dr. Anna Benjamin Pulimood, M.B.B.s., MD., ph.D.,
Chairperson, Research Committee & Principal
Dr. Biju George, M.B.B.s., MD., DM.,
Deputy Chairperson,
Secretary, Ethics Committee, IRB
Additional Vice-Principal (Research)
Dr. John Antony Jude
Prakash
MBBS. MD Professor, Clinical
Microbiology. CMC.
Vellore.
Internal,
Clinician.
Dr. Ajith Sivadasan MD, DM Professor, Neurological
Sciences. CMC. Vellore
Internal,
Clinician
We approve the project to be conducted as presented.
Kindly provide the total number of patients enrolled in your study and the total number of
Withdrawals for the study entitled: "sequencing and MALDI-TOF- tools for accurate
identification of Non-tuberculous Mycobacteria-a Pilot study" on a monthly basis. Please send
copies of this to the Research Office (pserirclr@cmcV4ofg.acfu)
Fluid Grant Allocation; ,,,, ''.,
A sum of t,OO,OO.lt- tNB 4fo, Z years. 50J00/- M(RupeesFifUThousandonlylwill begranted-forl2monthsasunlstln.stallnent. Therestofthe
50,000/- INR (Rupees Fiftv thousand onlv) each will be released at t.he end of thefirst )teur as 2
ndlnstallment. : r"-r
Yours sincerely, :it "'t:
Secretary (Ethics Committee)
Institutional Review Board
IRB Min. No. 1 1224 IDIAGNO] dated 05.03.2018 4of4
Ethics Committee Blue, Oftice of Research,
Tel: 041 6 
- 
2284294, 2284202
lst Floor, Carman Block, Christian Medical College, Vellore, Tamil Nadu 632 002
Fax: 0416 
- 
2262788, 2284481 E-mail: research@cmcvellore.ac.in
 id  sid  age  add  samp  growth  col  biochem  n16s  its  maldi  lpa  hiv  cd4  tb  ctb  tbsite  brect  copd  malig  trans  immsup line  linetype  pop  popsite  dm  prosthetic  device  sx  surg CD
1 TS 9257 31 Jharkhand sputum slow smooth creamNO ID M.intracellulare M.intracellulare M.intracellulareM.intracellulareno yes no PULMONARY yes no no no no no no no no no
2 MA 3078 28 West bengal lymph nodeslow smooth creamM.avium M.avium M.avium subsp.hominisuis M.avium M.avium yes 124 yes no PULMONARY no no no no no no no no no no PLHIV
3 MA 6141 55 Chattisgarh TBLB rapid smooth creamM.chelonae M.abscessus pending M.abscessusM.abscessus complexno yes no PULMONARY no no no no no no no no no no
4 TS 16379 49 Bihar sputum slow smooth creamNO ID M.intracellulare M.intracellulare No ID not done no yes no PULMONARY no no no no no no no no no no
5 MA 6457 46 West bengal sputum slow yellow M.intracellulareM.intracellulare M.intracellulare NO ID not done no yes no PULMONARY no no no no no no no no no no
6 MA 7789 23 Andhra sputum BMslow yellow M.intracellulareM.intracellulare M.intracellulare M.intracellulareM.intracellulareyes 6 no no no no no no no no no no no no DISSEMINATED
7 MA 6761 27 West bengal tissue biopsyrapid smooth creamM.abscessus M.abscessus pending M.abscessusnot done no no no no no no no no no n/a yes upper abbdomen cholecystecomyno no n/a yes CHOLECYSTECTOMY
8 MA 7746 74 Tamil Nadu sputum slow yellow NO ID M.simiae M.simiae M.simiae no ID no no no yes no no no no no no no no no
9 MA 9780 43 West bengal BAL slow fine coloniesNO ID M.europaeum M.europaeum M.gordonaenot done no no no yes no no no no no no no no no
10 TS 20977 59 Tamil Nadu sputum slow smooth creamNO ID M.simiae M.simiae M.simiae No ID no no no yes no no no no no no no no no
11 TS 19444 48 Andhra sputum slow smooth creamNO ID M.simiae M.simiae M.simiae not done no yes no PULMONARY no no no no no no no yes no no
12 MA 10633 57 Kerala sputum slow yellow NO ID M.simiae M.simiae M.simiae not done no no no no no no no no no no no no no
13 BA 39160 72 Bangladesh blood rapid smooth creamM.abscessus M.abscessus pending M.abscessusnot done no no no no no yes no yes no no yes no no INTRINSIC SECONDARY HYPOPITUITARISM ON STEROIDS
14 MA 9178 33 West bengal BAL slow smooth creamNOT DONE M.intracellulare M.intracellulare M.intracellularenot done no no no yes no no no no no no no no no
15 TB 1424 25 Jharkhand tissue biopsyrapid smooth creamM.abscessus M.abscessus pending M.abscessusnot done no no no no no no no no no n/a yes ANT ABD WALL LAPAROTOMYno no n/a yes LAPAROTOMY
16 MA 9742 71 West bengal sputum slow smooth creamNO ID M.intracellulare M.intracellulare M.intracellularenot done no no no yes no no no no no no no no no
17 MA 8645 45 West bengal BAL slow smooth creamNO ID M.intracellulare M.intracellulare NO ID M.intracellulareno yes no PULMONARY yes no no no no no no no no no
18 MA 8054 67 Tamil Nadu sputum rapid smooth creamM.abscessus M.fortuitum M.fortuitum M.fortuitum groupnot done no no no no no no no no no no yes no no
19 MA 5676 32 Jharkhand pus rapid smooth creamM.abscessus M.abscessus pending M.abscessusnot done no yes no NA no no no no no no n/a no n/a no no n/a no n/a SKULLBASE OSTEOMYELITIS WITH PARAPHARYNGEAL ABSCESS 
20 MA 4241 59 Tamil Nadu sputum slow yellow M.kansasii M.kansasii M.kansasii M.kansasii not done no yes no PULMONARY no no no no no no no yes no no
21 MA 8410 40 West bengal urine rapid smooth creamM.abscessus M.abscessus PENDING M.abscessusnot done no yes no GENITOURINARYno no no no no no no no no no
22 MA 5812 18 Jharkhand Lung biopsyrapid smooth creamM.fortuitum M.fortuitum M.fortuitum M.fortuitum groupnot done no yes no PULMONARY yes no no no no no no no no no CYSTIC BRONCHIECTASIS
23 MA 1101 58 Kerala urine rapid smooth creamM.abscessus M.abscessus Pending M.abscessusnot done no no no no no no no no no no yes yes DJ STENT no
24 BA 1983 50 Bangladesh blood rapid smooth creamM.abscessus M.abscessus PENDING M.abscessusnot done no no no no no no no no no no yes no yes PCI INFECTIVE ENDOCARDITIS- POST PTCA TO LAD
25 PT 4522 43 West bengal tissue biopsyrapid smooth creamM.abscessus M.abscessus PENDING M.abscessusnot done no no no no no no no no no n/a yes LEFT FOREARM FLEXORZONE INJURYno no n/a no n/a OLD INFECTED FLEXOR ZONE V INJURY
26 MA11199 26 Kerala BAL slow smooth creamNO ID M.avium M.avium subsp.hominisuis M.avium not done no no no no no no no no no no no no no
27 MA 11294 3 Tamil Nadu tissue biopsyslow smooth creamNO ID M.avium M.avium subsp.hominisuis NO ID not done no no no no no no no no no n/a no n/a no no n/a no n/a MIDDLE EAR BX- SCID T-B- NK+
28 BA 1988 66 Tamil Nadu blood rapid smooth creamM.abscessus M.abscessus PENDING M.abscessusnot done no no no no no no no no no no no yes TRACHEOSTOMYno C/C INFLAMMATORY DEMYELINATING POLYNEUROPATHY- PROB TB ON ATT
29 MA 9975 52 West bengal sputum slow fine coloniesNO ID M.intracellulare M.intracellulare NO ID not done no no no no yes no no no no no no no no
30 TS 622 37 Jharkhand sputum rapid smooth creamM.abscessus M.abscessus PENDING NO ID not done no yes no PULMONARY yes no no no no no no no no no
31 MA 9914 60 Kerala sputum slow yellow NO ID M.intracellulare M.intracellulare M.intracellularenot done no yes no DISSEMINATEDno no no no yes no no no no no
32 MA 1409 48 Andhra bone marrow biopsyslow smooth creamNO ID M.avium M.avium subsp.hominisuis M.avium not done yes 127 no no no no no no no no no no no no PROBABLE DISS MAC
33 MA 533 41 Andhra sputum rapid smooth creamM.fortuitum M.fortuitum PENDING M.fortuitum groupnot done no yes no PULMONARY no no no no no no no no no no
34 MA 1280 23 West bengal pus rapid smooth creamM.abscessus M.abscessus PENDING M.abscessusnot done no no no no no no no no no n/a no n/a no no n/a no n/a RT BREAST ABSCESS
35 EY 276 18 Tamil Nadu corneal scrapingrapid smooth creamM.abscessus M.abscessus PENDING M.abscessusnot done no no no no no no no no no no no yes AADI IMPLANT SCLERAL GRAFT LTyes SQUINT SX LEFT EYE
36 MA 6390 0 Andhra ETA rapid smooth creamM.abscessus M.abscessus PENDING M.abscessusM.abscessus complexno no no no no no no no no no no no no
37 MA 228 55 West bengal sputum slow smooth creamNO ID M.intracellulare M.intracellulare M.intracellularenot done no yes no PULMONARY yes no no no no no no no no no
38 TS 2315 48 Tamil Nadu sputum slow smooth creamNO ID M.longobardum M.celatum NO ID not done no no no no yes no no no no no yes no no SIGNI DOUBTFUL
39 BA 35338 26 Andhra blood rapid orange NO ID M.bacteremicum M.neoaurum M.neoaurumMycobacterium spp.no no no no no no no yes no no no no no NEUROMYELITIS OPTICA- ON STEROIDS, RITUXIMAB
40 BP 15000 2 Tamil Nadu blood rapid smooth creamM.abscessus M.abscessus PENDING M.abscessusnot done no no no no no yes no yes yes centralno no no no T CELL ALL ON RELAPSE PROTOCOL CHEMO
41 BA 33801 19 West bengal blood rapid smooth creamM.abscessus M.phocaicum Mycobacterium sp. P.stutzeri not done no no no no no no no yes yes central IJVno no no no MYASTHENIA GRAVIS ON IMMUNOMODULATOR-RITUXIMAB 
42 EY 323 67 Tamil Nadu corneal scrapingrapid smooth creamM.abscessus M.abscessus PENDING M.abscessusnot done no no no no no no no no no yes RIGHT EYE CATARACT SXno yes INTRAOCULAR LENSyes RT EYE CATARACT SX
43 MA 1362 20 Andhra lymph nodeslow smooth creamNO ID M.avium M.avium subsp.hominisuis M.avium not done yes 107 yes no DISSEMIINATEDno no no no no no no no no no PLHIV
44 TS 3958 31 Andhra sputum slow smooth creamNO ID M.yongonense M.intracellulare NO ID not done no no no no no no no no no no no no no
45 MA 365 42 Jharkhand sputum slow yellow NO ID M.szulgai M.szulgai M.szulgai not done no yes no PULMONARY no no no no no no no no no no
46 MA 136 69 Andhra sputum slow smooth creamNO ID M.intracellulare M.intracellulare M.intracellularenot done no no no yes no no no no no no no no no
47 MA 10996 33 Jharkhand bone marrow biopsyslow smooth creamNO ID M.intracellulare M.intracellulare M.intracellularenot done yes 5 no no no no no no no no no no no no DISSEMINATED
48 P 813 25 Tamil Nadu pus rapid smooth creamM.abscessus M.abscessus PENDING M.abscessusnot done no no no no no no no no no n/a no n/a yes no n/a no n/a TYPE I DM INJECTION ABSCESS
49 TS 23812 48 West bengal BAL slow yellow NO ID M.intracellulare M.intracellulare M.intracellularenot done no no no no yes no no no no no no no no
50 TS 20224 63 West bengal sputum slow smooth creamNO ID M.timonense M.timonense M.intracellularenot done no no no no yes yes no no no no no no no SIGNI TO CORRELATE CLINICALLY
51 MA 10818 50 West bengal BAL slow smooth creamNO ID M.intracellulare M.intracellulare M.intracellularenot done no no no yes no no no no no no no no no
52 MA 10489 57 Jharkhand sputum slow smooth creamNO ID M.avium M.avium subsp.hominisuis M.avium not done no yes no PULMONARY no no no no no no no no no no
53 MA 7165 45 Bangladesh pus rapid smooth creamM.abscessus M.abscessus PENDING M.abscessusnot done no no no no no no no no no n/a yes INCISIONAL HERNIAno yes MESH PLACEMENT FOR HERNIAno n/a n/a
54 BA 21926 38 Tamil Nadu blood rapid orange NO ID Mycobacterium spp Pending S.equorum Mycobacterium spp.no no no no no no no no no no no no no CONTAMINANTS INCL RAPIDLY GROWING NTM
55 TS 6440 40 Bihar sputum slow smooth creamNO ID M.intracellulare M.intracellulare NO ID not done no no no yes yes no no no no no yes no no
56 TS 7361 36 Bihar sputum slow smooth creamM.intracellulareM.intracellulare M.intracellulare M.intracellularenot done no yes no PULMONARY yes no no no no no no no no no
57 PP 1669 54 Tamil Nadu pus rapid smooth creamM.fortuitum M.fortuitum PENDING M.fortuitum groupnot done no no no no no no no no no n/a yes RT INGUINAL no yes MESH PLACEMENT FOR HERNIAyes n/a RT INGUINAL NONHEALING SURGICAL WOUND
58 TS 17410 54 Tamil Nadu sputum slow smooth creamNO ID M.avium complex M.intracellulare M.intracellularenot done no yes no PULMONARY yes no no no yes no no yes no no
59 MA 1251 34 Tamil Nadu pus rapid smooth creamM.abscessus M.abscessus PENDING M.abscessusnot done no no no no no no no no no n/a yes ABDOMINAL WALL PORT SITE INFno no n/a no n/a n/a
60 MA 833 48 Tamil Nadu sputum slow smooth creamNO ID M.simiae M.simiae M.simiae not done no yes no PULMONARY yes no no no no no no no no no
61 OH18554 41 Tamil Nadu sputum slow smooth creamNO ID M.avium complex M.intracellulare M.intracellulareM.intracellulareno yes no PULMONARY no no no no no no no no no no
62 OH 59 Kerala pus rapid smooth creamM.chelonae M.abscessus Pending NO ID not done no no no no no no no no no n/a yes INGUINAL regionno yes HERNIAL MESH yes INGUINAL HERNIOPLASTY
63 MA 7188 51 Tamil Nadu sputum slow dry cream NO ID M.intracellulare M.intracellulare M.intracellulareM.intracellulareno no no yes no no no no no no no no no
64 MA 6577 50 Tamil Nadu sputum slow smooth creamNO ID M.avium complex M.intracellulare NO ID M.intracellulareno yes no PULMONARY no no no no no no no no no no
65 TS 4243 30 Jharkhand sputum rapid smooth creamM.fortuitum M.fortuitum M.fortuitum M.fortuitum groupnot done no no yes PULMONARY no no no no no no no no no no NR
66 TS 6321 40 Bihar sputum rapid smooth creamM.fortuitum M.fortuitum M.fortuitum M.fortuitum groupnot done no yes no MDR PULMONARY TBno no no no no no no yes no no NR
67 MA 2470 72 Jharkhand bone marrow biopsyintermediateorange NO ID M.novocastrense PENDING M.flavescensnot done yes 132 yes no PULMONARY no no no no no no no no no no NR
68 TU 183 33 Tamil Nadu urine intermediateorange NO ID M.flavescens PENDING M.flavescensnot done no yes no TB MENINGITISno no no no no no no no yes URINARY CATHETERno NR
69 ID 41 Tamil Nadu sputum slow yellow M.kansasii M.kansasii M.kansasii M.kansasii not done no yes no PULMONARY no no no no no no no yes no no
70 TS 11537 46 Tamil Nadu BAL rapid smooth creamM.abscessus M.abscessus PENDING M.abscessusnot done no yes no PULMONARY no no no no no no no no no no
71 TS 6333 38 Bangladesh sputum intermediateorange NOT DONE M.flavescens PENDING M.flavescensnot done no no no no no yes no no no no no no no NR
72 MA 5496 47 West bengal pus rapid dry cream M.fortuitum M.fortuitum PENDING M.fortuitum groupnot done no no no no no no no no no n/a yes ABDOMINAL WALLno no n/a yes LAPAROSCOPIC APPENDICECTOMY
73 MA 4461 40 Nepal lymph nodeslow yellow NOT DONE M.simiae M.simiae M.simiae NO ID yes 81 yes no TB lymphadenitisno no no no no no no no no no AML PLHIV DISSEMINATED NTM
74 MA 5379 35 West bengal sputum slow yellow not done M.parascrofulaceum M.parascrofulaceum M.scrofulaceumnot done no yes no PULMONARY yes no no no no no no no no no
75 PP 3666 24 West bengal pus rapid smooth creamM.fortuitum M.fortuitum PENDING M.fortuitum groupnot done no no no no no yes no yes yes CENTRALno n/a no no n/a no n/a LINE ABSCESS
76 BV 428 53 West bengal catheter tiprapid smooth creamM.abscessus M.abscessus PENDING M.abscessusnot done no no no no no no no no no no no yes LAD STENT yes PTCA -2017 DEC
77 BV 433 15 West bengal catheter tiprapid smooth creamM.abscessus M.abscessus PENDING M.abscessusnot done no no no no no yes no yes no no no no no APML
78 PP 3761 27 Tamil Nadu pus rapid dry cream M.fortuitum M.farcinogenes PENDING M.fortuitum groupnot done no no no no no no no no no n/a no n/a no no n/a no n/a RT GLUTEAL ABSCESS
79 MA 3970 32 West bengal sputum slow yellow NO ID Mycobacterium spp. M.europaeum NO ID not done no yes no PULMONARY yes no no no no no no no no no NR
80 MA 6202 60 Chattisgarh pus rapid dry cream M.fortuitum M.fortuitum pending M.fortuitum groupNot done no no no no no no no no no n/a no n/a yes no n/a no n/a ABDOMINAL WALL INFN
81 MA 5388 47 Jharkhand sputum slow smooth creamnot done M.intracellulare M.intracellulare M.intracellulareM.intracellulareno yes no PULMONARY no yes no no no no no no no no
82 MA 7428 29 West bengal bone marrow biopsyrapid smooth creamM.abscessus M.mucogenicum pending M.mucogenicumnot done no no no no no no no no no no no no no PUO X 4MO WITH SPONDYLODISCITIS AND MONOARTHRITIS RT KNEE
83 MA 5415 48 Bangladesh BAL slow yellow NOT DONE M.scrofulaceum M.europaeum NO ID NO ID no yes no PULMONARY yes no no no no no no no no no
84 TS 12900 37 Jharkhand sputum slow smooth creamNOT DONE M.intracellulare M.intracellulare M.intracellularenot done no yes no PULMONARY yes no no no no no no no no no
85 TP 170 50 Tamil Nadu pus rapid smooth creamM.abscessus M.abscessus PENDING M.abscessusnot done no no no no no no no no no n/a no n/a no no n/a no n/a SINUS DISCHARGE
86 OH-SRICHITRA 27 Kerala blood rapid smooth creamM.abscessus M.abscessus PENDING M.abscessusnot done no no no no no no no no no no no no no AORTIC ROOT ABSCESS
87 MA 6979 24 Tamil Nadu sputum slow yellow not done M.simiae M.simiae M.simiae not done yes 251 no no no no no no no no no no no no
88 AFB 436 24 Karnataka pus rapid smooth creamM.abscessus M.abscessus Pending M.abscessusM.abscessus complexno no no no no no no no no n/a yes LSCS with dehiscenceno no n/a no n/a n/a
89 BT 7770 22 Karnataka blood rapid dry cream M.fortuitum M.fortuitum Pending M.fortuitum groupM.f rtuitum group no no no no no no no no no no no no DAMA
90 MA 4527 74 Andhra sputum slow smooth creamnot done M.simiae M.simiae M.simiae M.intracellulareno no no no yes no no no no no no no no
